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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disease in which the
brain progressively deteriorates resulting in cognitive decline, language
impairment, diminished spatial awareness, memory loss and ultimately, death.
AD is the most prevalent neurodegenerative disease and the number of people
afflicted by AD is expected to more than double in the next 30 years. AD is
characterized in part by the formation of amyloid plaque deposits in the brain. It is
known that these plaques are composed of the peptide Aβ, which aggregates as
a function of age and is produced locally within the brain by cleavage of the
Amyloid precursor protein (APP). It is now recognized that type 2 diabetes is a
risk factor for the development AD and the AD brain has impaired insulin
signaling. Transgenic mice lacking the APP gene show broad changes in
metabolism, suggesting APP may play an important in regulating metabolic
homeostasis. This dissertation consists of two central studies aimed at
understanding the relationship between APP and insulin signaling. The first aim
is to examine the role APP plays in plaque formation within the pancreas and to
understand APP’s contribution to endocrine pancreas physiology. The second
aim is to examine the role APP plays in the regulation of the Insulin Degrading
Enzyme (IDE).
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In the first study, APP is found to be present in the pancreas and
overexpressed within the insulin producing β cells in the APP/PS1 mouse model
of AD. APP presence and overexpression does not result in the formation of the
Aβ peptide or plaques, but instead APP is processed through α-secretase
pathway to yield sAPPα. In primary cultures of pancreatic islets, increased APP
expression results in increased insulin secretion. sAPPα was detected in the cell
conditioned media of pancreatic islet primary cell cultures. Application of
recombinant sAPPα to both human and mouse pancreatic islet cultures
potentiates glucose stimulated insulin secretion. This effect is observed when
sAPPα was applied to the Min6 pancreatic β cell line. The BACE2 enzyme, an
APP cleaving α-secretase enzyme, localizes to pancreatic α cells. Additionally,
increased protein levels of IDE are observed in both pancreatic tissue lysate and
primary islet cultures of mice lacking the APP gene (APP-/-).
In the second study, we found IDE protein is found be increased in
numerous tissues including muscle, liver and brain from the APP-/- mouse
compared to wild type (WT) controls. IDE mRNA levels are also found to be
increased in APP-/- animal brain tissue. IDE protein is ubiquitous in the brain and
is detectable in neuron, astrocyte and microglia primary cell cultures. APP-/primary cultures of these cell types shows increased protein levels of IDE. siRNA
knockdown of APP is sufficient to increase IDE protein in a cell line. IDE activity
is found to be increased in APP-/- tissues. APP-/- brain tissue shows diminished
levels of insulin signaling and reduced insulin content. Synaptosomes stimulated

xiv

acutely with insulin from APP-/- animals show diminished insulin signaling
compared to WT synaptosomes.

xv

CHAPTER I
INTRODUCTION
Preface
The topic of this dissertation is focused on the role of the amyloid
precursor protein (APP) and its contribution to insulin homeostasis. APP is
established to play a central role in the pathology of Alzheimer’s Disease. Insulin
signaling and metabolic homeostasis are important factors in influencing the
progression of the disease. Elucidating the precise physiologic role APP plays in
metabolic function and insulin signaling is essential for understanding the
pathophysiology of this debilitating neurodegenerative disease.
For this dissertation, two separate studies were conducted involving the
role of Amyloid precursor protein and its role in the production, secretion and
clearance of the insulin peptide. The first study examines the amyloid precursor
protein in the pancreas and tests the hypothesis that Alzheimer’s disease-like
peptide plaques can form in the insulin producing β-cells to cause local cell
death, insulin insufficiency and glucose intolerance. The second study builds off
of findings in the first and examines the role of amyloid precursor protein in both
the central nervous system and peripheral organs to test the hypothesis that APP
acts as a negative regulator of the Insulin Degrading Enzyme (IDE).

1

History and Discovery of the Amyloid Precursor Protein
The Amyloid precursor protein and its role in health and disease is
perhaps best understood in the context of its discovery. During the early 19th
century the German physician Alois Alzheimer reported the case of a female
patient with unusually advanced dementia for her age. The patients’ health
quickly deteriorated and she soon passed away. Following her death, Alois
performed an autopsy of the patient’s brain and was surprised to observe what
would become known as the hallmarks of “Alzheimer’s Disease” (AD). These
observations included the formation of aggregated “plaques” and intracellular
“tangles” in brain tissue as well as changes in the lipid composition of the brain
(Alzheimer, Stelzmann, Schnitzlein, & Murtagh, 1995).
It was not until several decades later that the physical composition of
these plaques was elucidated by the chemists Glenner and Wong, who revealed
that these seemingly neurotoxic plaques were actually formed of a selfaggregating peptide approximately 40 amino acids in length (Glenner & Wong,
1984). Around this same time it was recognized that the plaques observed in AD
brains were chemically identical to the plaques found in the brains of aged
patients with Downs Syndrome (Masters et al., 1985).
It was hypothesized that the plaque forming peptide, now termed Amyloid
Beta (Aβ), may actually be cleaved from a larger protein. The pursuit of this
hypothesis lead to the landmark discovery of the Amyloid precursor protein
(APP) in 1987 (Kang et al., 1987). The gene encoding APP in humans was
confirmed to be located on chromosome 21, thus it is believed that humans
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afflicted with Downs Syndrome have an extra copy of the gene which results in
increased APP and consequently more Aβ production (Blanquet et al., 1987;
Robakis et al., 1987). The discovery of APP and subsequent research revealed
that it is a transmembrane protein resembling a cell surface receptor and is
ubiquitous throughout the body, but especially abundant in nervous tissue
(Selkoe et al., 1988).
APP in AD: The Amyloid Hypothesis
The theory that Alzheimers Disease is caused by the buildup of toxic Aβ in
the brain known as the Amyloid Hypothesis. After APP was discovered, it was
generally recognized that for the Aβ peptide to become liberated from the larger
Amyloid precursor protein, proteolytic enzymes would likely be required. The
locations of the amino acids within APP that must be hydrolyzed to generate Aβ
peptide could be logically deduced from the known sequences of APP and Aβ.
Thus, during the 1990’s several independent research groups sought to identify
the proteolytic enzymes, termed “secretases” which could cut the APP protein at
these defined sites. It was hoped that identification of these enzymes could lead
to pharmacological targets. In 1995 the γ-secretase enzyme was identified, and it
was revealed that mutations in this enzyme lead to early onset AD (Levy-Lahad
et al., 1995; Sherrington et al., 1995). This finding, along with the finding that
certain familial mutations in APP drive another form of early onset AD, greatly
bolstered the evidence for the Amyloid Hypothesis (Citron et al., 1992). It is now
accepted that Aβ and its aggregated oligomeric forms are generally neurotoxic.
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At this present time, the Amyloid Hypothesis remains the dominant theory of AD
(Selkoe & Hardy, 2016).
The Physiologic Role of APP
Structure, Expression and Processing of APP
APP is a single pass transmembrane protein with a small intracellular cterminal region, and a large extracellular n-terminal region (Kang et al., 1987; U.
C. Muller & Zheng, 2012). The protein is trafficked to the cell membrane via the
conventional secretory pathway, and contains a YENPTY motif on its c-terminus
for clathrin-mediated endocytosis (Jacobsen & Iverfeldt, 2009; Muresan &
Ladescu Muresan, 2015). Numerous isoforms of the APP gene have been
reported, but three isoforms in particular seem to be most abundant (Golde,
Estus, Usiak, Younkin, & Younkin, 1990; Pan, Monteggia, & Giordano, 1993;
Selkoe et al., 1988). Neurons produce the relatively lower molecular weight 695
amino acid APP, while most other cell types including glial cells produce the 750
to 770 amino acid isoforms. Alternative splicing of APP varies with tissue and cell
type (Nalivaeva & Turner, 2013). Unlike the APP695, the heavier molecular
weight isoforms of APP contain a Kunitz protease inhibitor domain and heparin
binding domain which may be important for their function.
Mature APP protein can be enzymatically processed by a variety of
secretases, resulting in the formation of different APP fragments ranging from
small peptides to large soluble 100 kilodalton proteins. In general, this processing
is described as “amyloidogenic” or “non-amyloidogenic”, meaning producing or
not-producing Aβ respectively. Amyloidogenic processing of APP involves the
4

cleavage of APP by the BACE1 enzyme (β-secretase) on the extracellular
domain, followed by cleavage of APP within the cell membrane by the γsecretase protein complex to ultimately yield the Aβ peptide along with a
secreted APP fragment sAPPβ (Selkoe & Hardy, 2016; Sinha et al., 1999;
Vassar et al., 1999; Yan et al., 1999). In non-amyloidogenic processing, the APP
protein is cleaved within the Aβ sequence by one of the many α-secretase
enzymes resulting in the release of the large sAPPα fragment extracellularly,
where it is thought to act as a ligand for a variety of receptors (Habib, Sawmiller,
& Tan, 2017).
In addition to processing mechanisms involving the ectodomain of APP,
the intracellular domain of APP can also be cleaved to yield a short peptide
fragment known as AICD (APP Intracellular Domain). This AICD region of APP
contains the YENPTY signal sequence and interacts with a variety of other
proteins. AICD is thought to be involved in the regulation of gene expression
(Kimberly, Zheng, Guenette, & Selkoe, 2001).
The APP Protein Family
The APP protein is part of a family of three known proteins including APP,
APLP1 and APLP2 (U. C. Muller & Zheng, 2012). Like APP, APLP1 and APLP2
are both single pass transmembrane proteins. APLP1 and APLP2 are processed
similarly to APP, but cannot produce Aβ due to the lack of the amyloidogenic Aβ
sequence within them (Eggert et al., 2004; Li & Sudhof, 2004). APLPs are
capable of being processed through both α and β secretase processing
mechanisms. Like APP, the extracellular domain of the APLPs is released into
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extracellular space when the proteins are cleaved by α-secretase. This protein
fragment is termed either sAPLP1α or sAPLP2α (Walsh et al., 2007). While APP
and APLP2 are ubiquitously expressed, APLP1 expression is limited to the brain
(Lorent et al., 1995; Wasco et al., 1993).
Functions of APP and APLPs in the Brain and Peripheral Organs
The APP family of proteins is widely conserved among species and
present in numerous multicellular organisms, suggesting the gene is biologically
important or advantageous in survival and proliferation (Tharp & Sarkar, 2013).
While the role of APP in the generation of Aβ is now well characterized, the
physiologic functions of APP are less certain. Studies in transgenic animals have
revealed that the APP family of proteins is required for survival, implying these
proteins perform an essential biological function (Heber et al., 2000; Needham et
al., 2008). Specifically, studies in transgenic mice reveal that mice must express
either the APP or APLP2 gene in order to survive and develop normally past the
neonatal stage. Experimental evidence suggests this lethality may be due in part
to robust deficits in the development of the neuromuscular junction (Klevanski et
al., 2014; P. Wang et al., 2005). Curiously, this fatal double knockout mouse for
APP and APLP2 is hypoglycemic before death (Needham et al., 2008). Genetic
ablation of just APP alone confers a more benign phenotype, with significant
reductions in mouse brain volume, animal size, body weight, serum glucose and
changes in whole body metabolism (U. Muller et al., 1994; Needham et al., 2008;
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Puig et al., 2017; Zheng et al., 1995). As in mice, in the nematode C. elegans,
ablation of the APP homologue APL-1 is lethal (Ewald & Li, 2012).
Functional characterization of the APP family of proteins highlights their
importance, particularly in the central nervous system. The APP family of
proteins have been characterized as synaptic adhesion molecules and
upregulated during synaptogenesis (Schilling et al., 2017). Furthermore, the full
length APP protein itself is believed to be involved in certain signaling processes
and may function as a cell surface receptor for extracellular ligands (Hass &
Yankner, 2005; Kang et al., 1987; B. Wang et al., 2017). APP and sAPPα play a
role in neurite outgrowth and neuronal migration (Gakhar-Koppole et al., 2008;
Hasebe et al., 2013; Ramaker, Swanson, & Copenhaver, 2016). sAPPα has also
been shown function as a neurotrophic factor and may play neuroprotective role
in the central nervous system (Fol et al., 2016; Hick et al., 2015; Weyer et al.,
2011). Additionally, characterization of aged APP-/- mice has revealed that these
animals have fewer dendritic spines in addition to learning deficits (K. J. Lee et
al., 2010; Tyan et al., 2012). Taken together, these studies suggest APP and its
metabolites influence a variety of cellular processes within the brain and are of
particular importance in synapse development and function.
Outside of nervous cells, APP has been implicated in a diverse set of
biological processes. In immune cells, APP has been demonstrated to be
upregulated under pro-inflammatory conditions and may serve roles in cell
migration and adhesion as well as regulating general immune cell phenotype
(Banati et al., 1993; Manocha et al., 2016; Puig et al., 2017; Sondag & Combs,
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2004, 2010). In the skin, APP has a role in regulating cell proliferation and
maturation (Herzog, Kirfel, Siemes, & Schmitz, 2004; Hoffmann, Twiesselmann,
Kummer, Romagnoli, & Herzog, 2000). In skeletal muscle tissue, sAPPα has
been shown to potentiate glucose uptake and APP localizes to the
neuromuscular junction with acetylcholine receptors (Hamilton et al., 2014; P.
Wang et al., 2005). APP is also present is adipose tissue, where it seems to be
upregulated under certain pro-inflammatory conditions and through certain
cytokines (Puig, Floden, Adhikari, Golovko, & Combs, 2012; Sommer et al.,
2009). APP can be detected in intestinal tissue associated enteric nervous
system. Its presence plays a role in nutrient uptake and overall intestinal
phenotype (Puig, Lutz, et al., 2015; Puig, Manocha, & Combs, 2015; Puig,
Swigost, Zhou, Sens, & Combs, 2012). These studies are but a fraction of the
wide array of research documenting the varied and numerous roles of APP in
peripheral organs. With increasing research it is becoming clear that the role of
APP in each tissue changes depending on the physiological function of the organ
and the types of proteins which can both interact with and process APP locally.
General Overview of AD
Alzheimer’s disease has become the most prevalent neurodegenerative
diseases and a leading cause of death of the elderly. Approximately 5.5 million
people in the United States are currently afflicted with AD, and the incidence of
the disease is expected to rise to approximately 13.8 million people by 2050
(Taylor, Greenlund, McGuire, Lu, & Croft, 2017). AD is progressive and
neurodegenerative, and is characteristic in its progression by affecting particular

8

regions of the brain more prominently than others. The limbic system and
temporal lobes, including the hippocampal formation of the brain are dramatically
affected and show pathological changes early in the disease (Braak & Braak,
1997a, 1997b). Pathological hallmarks of AD include Aβ plaque deposits in the
brain and blood vessels, as mentioned above, and the hyperphosphorylated
protein Tau which forms intracellular tangles. The regions of the brain affected
are critically involved in both the formation and storage of memories, thus their
degeneration results in the notorious phenotype of memory which occurs in AD
(Teyler & Rudy, 2007). In addition, notable language impairment and spatial
memory deficits are observed in AD (Morello, Lima, & Brandao, 2017). At this
time there are no available cures for the disease. Therapies which combat the
symptoms of AD are available, but limited in their effectiveness (C. Zhang, 2017).
Ultimately, affliction with AD results in the death of the patient. In the United
States 3.6% of all premature death is due to AD (Taylor et al., 2017).
Metabolic Dysfunction and Alzheimer’s Disease
Brain Glucose Hypometabolism in Alzheimer’s Disease
Glucose is essential for normal brain function and brain development
(Burns, Rutherford, Boardman, & Cowan, 2008; Cornblath & Reisner, 1965).
While the brain can utilize ketones as a source of fuel during prolonged fasting
and starvation, glucose serves as the primary energy source for the brain.
Severe hypoglycemia results in coma and eventually, death. To preserve
function and survival, the brain tightly regulates blood glucose levels and food
intake (Xu, O'Malley, & Elmquist, 2017). The brains ability to regulate blood sugar
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was first demonstrated by the French physiologist Claude Bernard in 1854.
Bernard found that by lesioning the floor of the brain’s fourth ventricle in rabbits
blood sugar levels would subsequently increase (Tups, Benzler, Sergi, Ladyman,
& Williams, 2017).
In the 1980s, the German physician-scientist Siegfried Hoyer was the first
to hypothesize that metabolic dysfunction may play a role in the pathogenesis of
Alzheimer’s disease and age related cognitive decline. In his time, Hoyer’s
theories were controversial as they challenged the more traditional “plaques and
tangles” view of AD. Specifically, Hoyer observed that glucose metabolism was
significantly impaired in the brain of patients with advanced AD, compared to
aged matched controls (Hoyer, 1982, 1986). In one patient cohort, he observed
more than a 40% reduction in the metabolic rate of glucose of AD patients
(Hoyer, Oesterreich, & Wagner, 1988). Hoyer’s seminal observations have been
further validated over the years by several researchers (Meier-Ruge, BertoniFreddari, & Iwangoff, 1994; Sugimoto et al., 2017). This pattern of impaired and
regional glucose hypometabolism is not restricted to AD, but is also observed in
aged patients with Downs syndrome (Lao et al., 2018). Curiously, this
phenomenon in some cases seems to precede, and cannot solely be explained
by, changes in gray matter volume in the brain (Wirth et al., 2017). Glucose
hypometabolism is also observed in the brains of various animal models of AD
(Dodart, Mathis, Bales, Paul, & Ungerer, 1999; Macdonald et al., 2014; Sadowski
et al., 2004). In the McGill-R-Thy1-APP rat model of AD, which overexpresses a
human mutant APP to produce Aβ aggregates in the brain, glucose
10

hypometabolism is observed in aged animal brains along a similar time course
with development of Aβ plaque deposits (Parent et al., 2017). This observation,
which is dependent on brain cells taking up the radiofluorinated glucose molecule
[18F]FDG, has been shown to be a signal of impaired energy consumption in both
neurons and astrocytes (Zimmer et al., 2017). The time course of brain
hypometabolism across AD animal models and its detectability in Aβ driven
models of AD suggest Aβ may be the primary molecular mediator of this
phenomenon. However, this does not preclude the possibility that
hypometabolism is critically involved in the pathophysiology and development
of AD.
Insulin and Insulin Receptor in the Brain
For several decades, it was believed that insulin does not play an
important role in brain physiology. This assumption was based on the
experimental observation that brain glucose uptake is not robustly stimulated by,
or dependent on, insulin in vivo (Best, Taborsky, Halter, & Porte, 1981; Goodner,
Hom, & Berrie, 1980; Hertz, Paulson, Barry, Christiansen, & Svendsen, 1981).
Furthermore, the cells of the brain including neurons were found to utilize
different glucose transporters than the insulin sensitive muscle and adipose cells.
Neurons primarily utilize the high affinity transporter Glut3, while skeletal muscle
and adipose tissue express insulin responsive Glut4 (Stringer, Zahradka, &
Taylor, 2015). The brain was thus deemed to be an insulin-insensitive organ.
However, more recently, numerous research findings have done much to shift
this paradigm and it is now generally accepted that both insulin and the insulin
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receptor play a significant role in brain function and brain regulation of peripheral
metabolism (Kleinridders, Ferris, Cai, & Kahn, 2014).
While the vast majority of insulin in the human body is synthesized in the β
cells in the islets of Langerhans of the pancreas, both the insulin peptide and
insulin mRNA are detectable in the brain, suggesting the brain may produce
small amounts of insulin locally (Devaskar et al., 1994; Devaskar, Singh,
Carnaghi, Rajakumar, & Giddings, 1993). Insulin has also been detected in
primary neuron cultures (D. W. Clarke, Mudd, Boyd, Fields, & Raizada, 1986). In
addition, insulin is actively transported across the blood-brain barrier (Baura et
al., 1993). Increases in peripheral insulin have been shown to activate insulin
signaling in specific regions of the brain (Kleinridders et al., 2013). The insulin
receptor (IR) is distributed throughout the brain including the olfactory bulb and
hypothalamus and is particularly abundant in the hippocampus, cortex and
thalamus (Kleinridders et al., 2014). Much of what is known about the role of the
insulin receptor in the brain comes from the brain-specific IR knockout mouse
generated by the lab of Dr. Ronald Kahn (Bruning et al., 2000). These animals
show changes in feeding behavior, become obese and insulin resistant and also
develop hypothalamic dysfunction. Thus, brain IR is thought to play an essential
role in regulating metabolism in the periphery. Additionally, insulin is thought to
participate in the normal function of the brain. Infusion of insulin into the rat brain
improves performance in spatial memory tasks (Biessels et al., 1998; Park,
Seeley, Craft, & Woods, 2000). The hippocampus is essential for learning and
memory and insulin is now believed to play an important role in hippocampal
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function. Insulin has been shown to modulate the activity of hippocampal neurons
and likely plays an important role in synaptic plasticity and long term potentiation
(van der Heide, Kamal, Artola, Gispen, & Ramakers, 2005). This finding has
been further validated by the fact that insulin has been shown to have
comparable roles in activating signaling cascades and affecting neuron function
in other neuronal types (Klockener et al., 2011). In stark contrast to the previous
dogma of insulin’s role in the brain, recent evidence also suggests insulin plays a
surprising role in brain energy utilization. In astrocytes, which are the most
abundant cell in the brain, insulin has been shown to enhance glucose uptake
and regulate metabolism. Insulin, in cooperation with the related insulin-like
growth factor 1 (IGF-1) enhances glucose uptake by regulating the activity and
subcellular location of the Glut1 transporter (Fernandez et al., 2017; HernandezGarzon et al., 2016). Furthermore, insulin mediated astrocyte glucose uptake is
critical for brain regulation of peripheral metabolic processes and also regulates
glucose flux across the blood-brain barrier (Garcia-Caceres et al., 2016).
Insulin and Insulin Resistance in Alzheimer’s Disease
Given the important roles of insulin in the brain it is not surprising that
insulin resistance is associated with cognitive dysfunction and
neurodegeneration. Human patients with type 1 or type 2 diabetes have
accelerated cognitive decline as they age, in addition to behavioral changes
(Biessels, Deary, & Ryan, 2008). Furthermore, epidemiological evidence has
implicated type 2 diabetes (T2DB), or insulin resistance, as a risk factor for AD,
and T2DB has been shown to more than double the risk of developing late onset
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AD (Mittal & Katare, 2016; Vagelatos & Eslick, 2013). Metabolic dysfunction in
general, including obesity, also accelerates the progression of cognitive decline
and dementia (Beydoun, Beydoun, & Wang, 2008). Some researchers are now
considering Alzheimer’s disease as a third form of diabetes, or type 3 diabetes
(de la Monte, 2014). This hypothesis states that insulin resistance in the brain is
a causative factor in AD. The experimental basis of this hypothesis is largely
grounded in the work published by Talbot et. al in 2012 (Talbot et al., 2012).
Talbot performed human brain tissue slice cultures from both AD patients and
age matched controls. These slices were then stimulated with near physiologic
levels (1-10 nM) of either insulin or IGF-1, and the induction of the insulin
signaling cascade was measured by assessing multiple markers including
phosphorylation of the insulin receptor and other downstream markers such as
pAKT and pIRS. Talbot observed significant insulin signaling resistance and IGF1 signalling resistance in the AD brain, including in the hippocampus. This
provided the first experimental evidence demonstrating significant insulin
resistance in the human AD brain.
The relationship between insulin and AD extends to animals models. In
modeling type 1 diabetes, a disease of insufficient insulin production, researchers
often utilize the toxin streptozotocin (STZ). STZ selectively kills the insulinproducing β cells of the pancreas, resulting in insulin insufficiency and
consequently hyperglycemia. It has been found that monkeys treated with STZ
develop AD-like pathology in the brain. This includes increased levels of Aβ in
the hippocampus, changes in Tau phosphorylation and perturbations of several
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insulin signaling markers within the brain (Morales-Corraliza et al., 2016).
Injections of Aβ oligomers into the monkey brain also cause insulin resistance
directly in the CNS, an effect which is rescued with insulin sensitizing GLP-1
receptor agonists (Bomfim et al., 2012). Hyperglycemia, glucose intolerance and
insulin resistance have been noted across several mouse models of AD. These
metabolic perturbations occur as a function of age and are exacerbated by high
fat diet or STZ-induced insulin insufficiency, suggesting that maintaining
peripheral metabolic homeostasis is an important factor in the progression of the
AD phenotype (de la Monte, Tong, Schiano, & Didsbury, 2017; Macklin et al.,
2017; Vandal et al., 2015; Vandal et al., 2014). Hyperglycemic clamp and
microdialysis experiments in rodents demonstrate that hyperglycemia alone is
sufficient to drive increased production of Aβ in the CNS in vivo (Macauley et al.,
2015). Interestingly, Aβ alone may not be the sole mediator of insulin
dysregulation in the brain. In addition to Aβ deposits in the brain, intracellular Tau
“tangles” are a known pathological feature of the AD brain. Tau has recently
been identified to being a potent regulator of insulin signaling in the brain, and
deletion or loss of function of Tau drives brain insulin resistance (Marciniak et al.,
2017).
In addition to the view that peripheral metabolic defects may drive the
pathogenesis of AD, experimental evidence also suggests that increasing Aβ
concentrations in the brain is sufficient to induce diabetes and aberrant wholebody metabolism. Intracerebroventricular injections of Aβ oligomers into the
brains of mice results in peripheral glucose intolerance, possibly due to damage
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induced to the hypothalamus. In TNFα receptor knockout mice increasing brain
Aβ does not result in glucose intolerance, suggesting that inflammation plays a
necessary role in this phenomenon (J. R. Clarke et al., 2015). Brain-specific
knock-in of BACE1 (β-secretase) causes diminished brain glucose uptake and
systemic diabetes as a function of age, suggesting that increased brain amyloid
burden is the direct mediator of peripheral metabolic dysfunction observed in
Alzheimer’s (Plucinska et al., 2016). In total, these studies demonstrate that
peripheral metabolism and insulin production play a direct role in regulating the
progression of AD in the brain, and conversely, that the health of the brain plays
a direct role in regulating peripheral metabolism and insulin sensitivity.
Aβ as a Promoter of Insulin Resistance
In vitro experiments have provided additional mechanistic insight into the
role of the Aβ peptide in disrupting insulin signaling. The Aβ peptide monomer
has been shown to directly bind the insulin receptor. Binding of Aβ to the IR is
competitive with insulin and does not stimulate IR. Increasing concentrations of
Aβ inhibit IR phosphorylation and downstream signaling in the presence of
insulin, thus Aβ acts something like a competitive antagonist. This antagonistic
effect of Aβ for the IR is observed for both the 40 and 42 amino acid lengths of
the Aβ peptide and interestingly, is not observed if the sequence of amino acids
in Aβ is modified (Xie et al., 2002). It is reasonable to question if Aβ-IR
interaction occurs in vivo. The estimated Ki of this competitive interaction is in the
micromolar range (8 µM). This far exceeds the normal physiologic concentrations
of Aβ in human cerebral-spinal fluid which are in the nanomolar range or less
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(Schirinzi et al., 2017). Micromolar concentrations of Aβ have also been shown to
antagonize the effect of insulin when applied to rat hippocampal and cortical
synaptosomes (Heras-Sandoval, Ferrera, & Arias, 2012). Insulin signaling in
cultured cells has been shown to be disrupted by intracellular Aβ, which may
have more relevance in vivo (H. K. Lee, Kumar, Fu, Rosen, & Querfurth, 2009).
Curiously, Aβ and sAPPα seem to have antagonistic effects on insulin
receptor signaling. Stimulation of muscle or neuronal cultures with sAPPα
induces insulin signaling and has neuroprotective effects (Hamilton et al., 2014;
Jimenez et al., 2011). Viral mediated sAPPα overexpression has been shown to
have pro-cognitive effects in an AD mouse model (Fol et al., 2016). Furthermore,
stimulation of cells with insulin or sAPPα shifts APP processing from
amyloidogenic processing to non-amyloidogenic processing (Son et al., 2012; X.
Wang et al., 2014). sAPPα in particular has been shown to decreased BACE1
activity to reduce Aβ production (Obregon et al., 2012). However, insulin has
been shown to potentiate Aβ secretion in some cell types, though the effect of
this on AD progression is uncertain (Najem, Bamji-Mirza, Yang, & Zhang, 2016;
Tharp et al., 2016). Aβ oligomers have also been shown to inhibit insulin receptor
signaling in cultured cells. Treatment of primary hippocampal neuron cultures
with Aβ oligomers has been shown to downregulate IR expression (Liu et al.,
2014). It is possible to some extent that Aβ induced insulin resistance observed
in vivo is a secondary consequence of inflammation. Aβ oligomers are potent
pro-inflammatory agents, and inflammation has long been known to have a role
in inducing insulin resistance in tissues (Hotamisligil, 2006). Indeed, it has been
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shown that the some of the deleterious effects of Aβ oligomers on cognition are
dependent on promoting inflammation to impair insulin signaling (Lourenco et al.,
2013).
Insulin Degrading Enzyme in Alzheimer’s Disease
While mechanisms involving Aβ production have been the subject of
extensive research efforts, much less is known about Aβ clearance mechanisms
and their role in AD. During the 1990’s two enzymes were independently
identified as having the ability to catabolize the Aβ peptide; neprilysin (NEP) and
insulin degrading enzyme (IDE) (Howell, Nalbantoglu, & Crine, 1995; Kurochkin
& Goto, 1994). IDE is of particular interest because of its role in clearing insulin
from tissues, thus making it critically important in regulating insulin signaling. In
humans, IDE is located on chromosome 10 (Espinosa et al., 1991). Damage to
chromosome 10 in the region of IDE has been associated as conferring an
increased risk of developing AD (Bertram et al., 2000). Furthermore, tissue
samples from human families that are known to develop AD and also have
mutations in chromosome 10 have been shown to have decreased IDE activity
(Kim et al., 2007). These studies indicate IDE plays an important role in
protecting the brain against the development of AD. IDE polymorphisms have
also been found to be associated with the development of type 2 diabetes
(Karamohamed et al., 2003).
IDE is expressed throughout the body and plays an important role in
clearing insulin from traditionally insulin-sensitive tissues (Bondy et al., 1994).
When insulin stimulates its canonical receptor, the insulin-receptor complex can
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be endocytosed and the bound insulin degraded by IDE, or returned to the
plasma membrane and released back into circulation (Levy & Olefsky, 1987).
IDE has been shown to play a role in regulating cellular sensitivity to insulin
signaling. Degraded insulin peptide fragments still have some ability to bind and
activate the insulin receptor (Duckworth, 1988). The majority of IDE is located in
the cytosol, but the enzyme is also detected in endosomes, lysosomes and
mitochondria and is secreted in exosomes (Duckworth, Bennett, & Hamel, 1998).
Interestingly, IDE substrates are not determined by the presence of a particular
amino acid sequence, but by relative size and charge. In addition to insulin and
Aβ, IDE has been shown to degrade a wide range of substrates including amylin,
glucagon and the AICD fragment of APP (Kurochkin, Guarnera, & Berezovsky,
2018).
IDE is detectable in all of the major cell types of the brain including
neurons (Vekrellis et al., 2000). Microglia have also been reported to secrete IDE
which may play an important role in Aβ plaque clearance from the brain (Qiu et
al., 1998). Insulin competitively inhibits the degradation of Aβ by IDE, thus it has
been speculated that the hyperinsulinemia observed in type 2 diabetes may slow
clearance of Aβ in brain tissue (Kurochkin & Goto, 1994). IDE is one of the
strongest molecular links connecting AD and diabetes to date.
Intranasal Insulin as Therapeutic Agent in Alzheimer’s Disease
Given the important role of insulin in normal brain function and the
demonstrated insulin resistance observed in AD derived brain tissues, it stands
to reason that enhancing insulin signaling in the brain may serve as a therapeutic
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strategy to combat AD. However, increasing insulin concentrations in the brain
without altering systemic insulin levels and signaling represents a
pharmacokinetic challenge. Interestingly, intranasal administering of the insulin
peptide represents a possible solution. This possibility has now been tested in
humans and animals with remarkable results. In humans, it has been shown that
intranasal administration of insulin peptide results in significantly increased
concentrations of insulin peptide within the cerebral spinal fluid within 10 minutes
and peaks 30 minutes (Born et al., 2002). Importantly, intranasal insulin
administration does not robustly change plasma insulin concentrations. This
method of dosing insulin directly to the brain has also been demonstrated to work
in rodents (Salameh et al., 2015). Intranasal insulin administration has been
tested in mouse models of AD and has shown positive effects on memory and
cognition. Long term administration of intranasal insulin has shown shown to
promote neuron survival and stimulate insulin signaling (Apostolatos et al., 2012).
Additionally, in AD mice, long term intranasal insulin promotes neurogenesis and
rescues memory defects (Mao et al., 2016; Y. Zhang et al., 2016).
Clinical trials in humans utilizing intranasal insulin to attenuate cognitive
and memory deficits are currently ongoing. Evidence to this point has been
positive, suggesting that both acute and long-term administration improves
cognitive performance (Claxton et al., 2015; Craft et al., 2012; Craft et al., 2017).
This includes improved performance in verbal memory scores and selective
attention. At this time however, studies in ApoE4 allele patients are mixed.
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ApoE4 is a potent risk factor for AD and some evidence suggests intranasal
insulin is not effective in these patients (Rosenbloom et al., 2014).
The apparently promising results of these early clinical trials, prevalence
of AD in human populations and mounting evidence that insulin signaling and
resistance play a prominent role in the pathology of AD warrant the need for
additional studies into the biology of insulin in AD mediated neurodegeneration.
Dissertation Research Objective
This dissertation is intended to continue our laboratory’s efforts to
characterize the physiologic functions of APP and to also gain a greater
understanding of the relationship between insulin and Alzheimer’s disease. Our
lab has focused on understanding the biology of APP in a number of peripheral
organs including intestine, immune and adipose tissue in order to gain a greater
understanding of APP’s biology and its potential role in disease. Our attention is
primarily focused on APP function and processing and to look for downstream
changes which may be induced by APP loss or overexpression. The objective of
this dissertation is to characterize APP’s role in insulin homeostasis. We focus on
pancreatic dysfunction as it is a well-known factor in insulin resistant diabetes.
We also focus on the insulin degrading enzyme because of its established link as
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an enzyme linking diabetes and AD. This dissertation is broken into two studies
aimed at addressing the following questions:
1. What role does APP play in the function and pathophysiology of the
endocrine pancreas?
2. What is the relationship between APP and IDE expression and activity?
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CHAPTER II
METHODS
Animals
The APP knockout mice (APP-/-) strain B6.129S7-Apptm1Dbo/J, the
APP/PS1 transgenic mouse line, strain 005864 B6.Cg-Tg
(APPswe,PSEN1dE9)85Dbo/ Mmjax and wild type mouse line, C57BL/6, were
purchased from the Jackson Laboratory (Bar Harbor, Maine). The APP-/- mice
have the APP gene knocked out in the entire organism by the insertion of a
neomycin resistance cassette into the promoter region and Exon 1 of the APP
gene. The APP/PS1 mice express the Swedish mutation in APP and deltaE9
mutation in the PS1 gene under the control of the mouse prion promoter.
APP/PS1 mice have been shown to develop AD-like Aβ plaques within the brain
around 6 months of age. Females from all three strains of mice were collected at
2 and 12 months of age for analysis.
Animal Use
All animal use was approved by the University of North Dakota
Institutional Animal Care and Use Committee (UND IACUC) protocols 1505-4
and 0712-1C. Mice were provided food and water ad libitum and housed in a 12
h light/dark cycle. The investigation conforms to the National Research Council of
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the National Academies Guide for the Care and Use of Laboratory Animals (8th
edition).
Human Tissue
Acetone fixed 10µm healthy and diseased human pancreatic tissue
sections were obtained from Bio-Chain (Newark, CA, USA). Isolated pancreatic
islets were obtained from Prodo Labs (Aliso Viejo, CA, USA). Tissue use was
approved by the UND Institutional Review Board (protocol IRB-200412-198).
Western Blots
Whole pancreas, isolated murine islets and isolated human islets were
lysed in RIPA Buffer containing protease inhibitor (Sigma P8340, St. Louis, MO,
USA) on ice. Protein concentrations were determined using the Bradford method
(Bradford, 1976). In study II, Hippocampus, gastrocnemius muscle, liver and
primary cell cultures were lysed in RIPA Buffer containing protease inhibitor
(Sigma P8340, St. Louis, MO, USA) on ice. Protein concentrations were
determined using the Bradford method 5-10 µg of protein was resolved by 10%
SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for
1 hour in 5% BSA-TBST solution and then incubated overnight in 5% BSA-TBST
solution containing the primary antibody. The next day primary antibodies were
washed off the membrane with TBST and HRP-conjugated secondary antibodies
were applied to membranes in 5% BSA-TBST for 2 hours. Luminol
chemiluminescence was utilized for visualization of proteins.
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Immunohistochemistry/Immunofluorescence
Pancreatic tissue was fixed in 4% paraformaldehyde (PFA) and cut into
10µm serial sections by cryostat. Mouse brains were fixed in 4% PFA, embedded
in gelatin, and serial sectioned to a thickness of 40µm using a sliding microtome.
The tissue was incubated overnight in primary antibody diluted in a PBS based
solution (1% Triton X-100, 3% BSA, 2% horse serum). Vector VIP (Vector Labs,
Burlingame, CA, USA) was used as the chromogen for visible light microscopy.
For immunofluorescent co-localization, Alexa Fluor 594 and Alexa Fluor
488 conjugated secondary antibodies (Life Technologies, Carlsbad, CA, USA)
were used with a DAPI counterstain. Nonspecific binding of secondary antibodies
was assessed by applying only the secondary antibody in blocking PBS solution.
BACE2 epitope blocking peptide studies were conducted by incubating tissue
with 1 µg/mL anti-BACE2 antibody with or without 2 µg/mL BACE2 blocking
peptide (Abcam ab8392, Cambridge, UK). BACE2 staining was quantified by
using Photoshop CS6 software. Images of islets were converted to greyscale and
traced around the periphery to assess total islet BACE2 staining intensity. The
total islet staining intensity was divided by the total area assessed to normalize
for islet size. A total of twelve non-serial sections from 12 month old animals
(n=8) from each strain were stained and assessed in this manner. A minimum of
twenty islets from each strain of mice was analyzed for its BACE2 staining
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intensity. Values obtained from this analysis were normalized to the mean
staining intensity value of the wild type strain.
Thioflavin S Staining
Thioflavin S staining was optimized in APP/PS1 mouse brain tissue and
then performed in pancreatic tissue by first quenching endogenous fluorescence
by incubating slides in 0.2% Sudan Black dissolved in 50% ethanol for 5 minutes.
Slides were then washed in PBS and then incubated in 0.02% thioflavin S
dissolved in dH2O for 30 minutes. Slides were washed again in PBS then
dehydrated and coverslipped in Permount.
Antibodies
Antibodies against full length APP (ab32136), BACE2 (ab8025), glucagon
(ab10988), IDE (ab32216) and the insulin receptor (ab69508) were purchased
from Abcam (Cambridge, UK). Antibodies against insulin (L6B10), p-GSK3β
(D3A4), GSK3β (D5C5Z), p-AKT (193H12) and AKT (C67E7) were purchased
from Cell Signaling Technology, Inc. (Danvers, MA, USA). The monoclonal
4G8 antibody targeting the Aβ peptide used in these studies was purchased from
Covance (Princeton, NJ, USA) and is now available from Biolegend (San Diego,
CA, USA). Antibodies against the N-terminus of APP (MAB348), GLUT2 (071402), and GLUT4 (07-1404) were purchased from Millipore (Darmstadt,
Germany). Antibodies against GLUT1 (sc-7903), GLUT3 (sc-7682), and ZNT8
(sc-98243) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX,
USA).The antibody for amylin (250470) was purchased from Abbiotec (San
Diego, CA, USA). The antibody against human APP (803001) was purchased
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from Biolegend (San Diego, CA, USA). The antibody against Aβ oligomers
(11610) was purchased from Cayman Chemical (Ann Arbor, MI, USA). The
antibody against neprilysin (MAB1126) was purchased from R&D Systems
(Minneapolis, MN, USA).
Enzyme Linked Immunosorbent Assays (ELISA)
Human Aβ ELISA kits (Millipore, Darmstadt, Germany) were utilized for
quantitation of tissue and islet culture Aβ. Whole pancreas tissue was lysed in
radioimmunoprecipitation assay buffer (RIPA) to yield detergent soluble Aβ. Aβ in
islet cultures was assessed by hand picking islets directly from culture and lysing
20 islets of similar size from each animal in 100µl SDS-free Triton X-100 buffer.
This lysate was then pulse sonicated and the lysate Aβ immediately measured by
ELISA. To assess islets for quantitation of total pancreatic insulin and insulin
secretion from murine islets, a mouse insulin ELISA kit (Millipore ZRMI-13K,
Darmstadt, Germany) was used. Total pancreatic glucagon content was
assessed using a glucagon ELISA kit (R&D Systems, Minneapolis, MN, USA).
Tissue samples were normalized by total sample protein as determined by the
Bradford method. Human islet insulin secretion was quantified using a human
insulin ELISA kit (Invitrogen KAQ12511, Carlsbad CA, USA). ELISAs were
performed as recommended by the manufacturer’s instructions. Hippocampus
tissue was lysed in radioimmunoprecipitation assay buffer (RIPA) on ice. The
lysate was sonicated on ice. To assess total hippocampus insulin content a
mouse insulin ELISA kit (Millipore) was used. Insulin content was normalized to
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total sample protein as determined by the Bradford method. ELISAs were
performed as recommended by the manufacturer’s instructions.
Pancreatic Islet Isolation and Culture
Pancreatic islets were isolated from C57BL/6 and transgenic mice using
modifications of prior methods (Stull, Breite, McCarthy, Tersey, & Mirmira, 2012;
Szot, Koudria, & Bluestone, 2007). The pancreas was first perfused by
cannulating the bile duct with a combination of 1 mg/mL collagenase and
thermolysin (products C9407 and P1512, Sigma Aldrich, St. Louis, MO, USA) in
a sterile HBSS solution. The hepatic bile duct was closed using silk sutures prior
to protease injection to direct fluid into the pancreas. Whole pancreas was then
removed and placed in 50mL tubes containing HBSS on ice. To initiate digestion,
the tubes were then placed in a 37 degree water bath and digestion was
monitored with intermittent mechanical disruption. After approximately 10 to 15
minutes, islets were then isolated from crude tissue extract by density
centrifugation along a Histopaque (Sigma Aldrich, St. Louis, MO, USA) gradient
before further purification using 70 µm filters. Islets from individual animals were
cultured separately in RPMI 1640 (Sigma Aldrich, St. Louis, MO, USA) containing
5 mM glucose, 10% FBS, 1% glycine and 1% penicillin/neomycin/streptomycin.
Human cadaveric pancreatic islets were obtained from Prodo Labs (Aliso Viejo,
CA, USA) and cultured in RPMI 1640 (Sigma Aldrich, St. Louis, MO, USA)
containing 5 mM glucose, 10% FBS, 1% glycine and 1%
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penicillin/neomycin/streptomycin for 24 hours before experiments were
conducted.
Min6 Cell Line Culture and Glucose Stimulated
Insulin Secretion (GSIS) Assay
The murine MIN6 beta cell line was purchased from Addexbio
Technologies (San Diego, CA, USA). MIN6 cells were cultured in DMEM/F12
media (ThermoFisher Scientific, Waltham, MA, USA) supplemented with 15%
FBS and 0.05 mM 2-mercaptoethanol. MIN6 pseudoislets were produced by
seeding MIN6 cells in low-attachment cell culture plates (Product #3471)
(Corning Incorporated, NY, USA). Three days after seeding and pseudoislet
formation, MIN6 pseudoislets were utilized in a GSIS assay. Pseudoislets were
first removed from cell culture media by wheel pipette and placed into Krebs
Ringer buffer (137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5
mM CaCl2, 25 mM NaHCO3) containing .05% BSA and 3.7 mM glucose for 60
minutes. Following incubation, pseudoislets were placed in fresh Ringer buffer
and then ten pseudoislets of similar size were selected by wheel pipette and
placed into 1.5 mL tubes containing 300 µL Krebs Ringer Buffer with 3.7 or 16.7
mM glucose and 0.05% BSA. For sAPPα (Product S9564, St. Louis, MO, USA)
stimulation experiments, the glucose solution was supplemented with 1 or 10nM
sAPPα. After 1 hour of stimulation, supernatants were collected and frozen at -80
degrees. Insulin concentration was determined in supernatants using mouse
insulin ELISA kit (Millipore ZRMI-13K, Darmstadt, Germany).
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Human and Mouse Primary Islet Culture Glucose
Stimulated Insulin Secretion (GSIS) Assay
Human or murine islets were cultured for 24 hours in RPMI 1640 with
5 mM glucose and 10% FBS. Islets were hand-picked from culture and incubated
for 1 hour prior to the GSIS assay in Krebs Ringer buffer (137 mM NaCl, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3)
containing .05% BSA and 3.7 mM glucose. Following incubation, the islets were
placed in fresh Ringer buffer. 8-10 islets/experiment were then hand selected
and placed into sterile 1.5 mL tubes containing 300 µL Krebs Ringer Buffer with
glucose and BSA. For sAPPα (Product S9564, St. Louis, MO, USA) stimulation
experiments, the glucose solution was supplemented with 10nM sAPPα. For
human islet stimulations, a range of glucose concentrations were used (3.7, 10,
and 16.7 mM) to span from low to high concentrations. Due to limitations in
animal numbers of the WT, APP-/-, and APP/PS1 genotypes as well as the
increased time required to hand select islets from the 3 genotypes for multiple
conditions in the time sensitive GSIS assay, we chose the 5mM glucose
concentration for the murine islet stimulation since it is physiologically relevant
and we had observed the strongest and most consistent effect of sAPP
stimulation of human islets near this concentration. After one hour, supernatants
were frozen at -80 degrees. Samples were thawed and diluted using sterile
Ringer’s buffer prior to ELISA.
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Glucose Tolerance Testing
Study I: Two month old WT, APP-/-, and APP/PS1 animals were fasted for
5 hours before receiving 2g/kg glucose by oral gavage. Prior to gavage and at
times 15 minutes, 30 minutes, one hour and two hours after gavage blood
glucose was measured by tail clipping and the TRUEresult glucometer (Home
Diagnostics, Inc, Fort Lauderdale, FL, USA)
In study II, 12 month old male and female WT and APP-/- were fasted for
5 hours before receiving 2g/kg glucose by IP injection. Prior to injection and at
times 15 minutes, 30 minutes, one hour and two hours after gavage blood
glucose was measured by tail clipping and the TRUEresult glucometer.
RNA Extraction and RT-qPCR
Total RNA from hippocampal tissues (10mg) were isolated using Trizol
Reagent (Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer’s instruction. Briefly, the tissue samples preserved in Allprotect
Tissue Reagent (Qiagen Inc., Valencia, CA) were washed once with PBS and
homogenized in a Bullet Blender Storm 24 tissue homogenizer (Next Advance,
Inc., Averill Park, NY) using 5mm stainless-steel beads (Qiagen). Extracted RNA
samples were quantified using a NanoDrop spectrophotometer (Thermo Fisher
Scientific).
For each sample, a cDNA library was generated from 1 µg of total RNA
using iScript Reverse Transcription Supermix (Bio-Rad Laboratories, Hercules,
CA) per manufacturers specifications. A primer set for Ide (forward: 5’CTGTGCCCCTTGTTTGATGC-3’; reverse: 5’-GTTCCCCGTAGCCTTTTCCA-3’)
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previously described (Kurauti et al., 2017) and purchased from Millipore Sigma
(St. Louis, MO). qPCR was performed in triplicates using iTaq Universal SYBR
Green Supermix and CFX96 Touch™ Real-Time PCR Detection System with
CFX Manager Software 3.0 (Bio-Rad) as the operating platform. Ribosomal
protein S18 (PrimePCR SYBR Green Assay Rsp18, Bio-Rad) was used as a
reference gene and Rsp18 Cq values were used to normalize respective Ide Cq
values (ΔCq). Relative Ide mRNA expression was determined as 2-ΔCq and
shown as mean ± SEM for each mouse strain.
siRNA Knockdown of APP
siRNA mediated knockdown of the mouse APP gene in SIMA9 microglia
was achieved using Dharmacon (Lafayette, CO) Accell SMARTpool siRNA
(product E-043246-00-0050) or cells were treated with non-targeting siRNA
(product D-001910-01-50) as a control. siRNA was utilized by combining the
Accell siRNA with Accell delivery media per manufacturer’s instructions and cells
were treated with a working concentration of 1µM siRNA for 6 days. After 3 days
of treatment (72 hours), siRNA containing media was supplemented 1:1 with
normal DMEM/F12 with 10% FBS. SIMA9 cell protein was harvested on day 7 for
western blot analysis.
APP Plasmids and Transfections
pCAX APP 751 and pCAX APP 695 were a gift from Dennis Selkoe &
Tracy Young-Pearse and are available from Addgene as plasmids 30138 and
30137 (Young-Pearse et al., 2007). Plasmids were prepared using Qiagen
Endofree Plasmid Giga Kit (product 12391). Primary astrocyte cultures were
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transfected using lipofectamine 3000 (ThermoFisher Scientific) as per
manufacturer’s instructions.
Mouse Neuron Primary Culture
Neurons were cultured from WT and APP-/- embryonic brain tissue on
embryonic day 16. Pregnant mothers were killed using CO2 and cervical
dislocation. Embryos were harvested and brains placed into sterile dissection
media (.5mM EDTA, 100 µM EGTA, 5.5 mM glucose, in PBS). Meninges were
removed and both cortices were harvested and minced in dissection media then
added to 0.25% trypsin. Tissue was digested for 20 minutes at 37 degrees
centigrade. Digestion was terminated by adding 10 mL DMEM/F12 containing
10% FBS. The cells were allowed to settle in the bottom of the pipette tip and
then added to 10 mL of neurobasal media supplemented with B27 and LGlutamine, then triturated approximately 20 times. Cells were cultured in 6 well
plates coated overnight with poly-L-lysine. Neuron cultures were grown at 37
degrees in 5% CO2.
Mouse Microglia and Astrocyte Primary Culture
Microglia and astrocyte cultures were grown from 1 day old WT and APP/- neonate pups. Meninges were removed from pups and cortical tissue was
harvested in dissection media (.5mM EDTA, 100 µM EGTA, 5.5 mM glucose, in
PBS) on ice. Cortices were then digested in trypsin for 15 minutes. Digestion was
terminated using DMEM/F12 media containing 10% FBS. Each individual’s
cortical tissue was cultured separately in a T75 flask with 20 mL of DMEM/F12
supplemented with 10% FBS. Media was supplanted on day two and replaced
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after 1 week. After two weeks of culture, microglia were separated from
astrocytes by shaking flasks at 200 RPM for 45 minutes to 1 hour. Supernatant
was collected for microglia, while astrocytes adhered to flask and were removed
with trypsin. Astrocytes were then passaged and cultured on 6 well plates for
experiments.
IDE Activity Assays
The IDE activity assays were purchased from AnaSpec (Fremont, CA)
(Catalog # AS-72231). The IDE activity assay utilizes a FRET substrate, which
emits increased fluorescence when cleaved by IDE. Hippocampus tissue, liver,
and gastrocnemius muscle was collected on ice from WT and APP-/- animals.
Our preliminary experiments utilizing this assay suggested that IDE enzyme
activity is negatively affected by sonication. Tissue was homogenized on ice in
assay buffer using an automated mortar and pestle. 50uL of each individual
animal’s tissue homogenate was loaded into a well of a 96 well plate containing
50uL of substrate solution. The fluorescent intensity was measured on a
fluorescent plate reader (BioTek) using an excitation of 485 nm and emission of
528 nm at 5 minute increments. Fluorescent units measured were converted to
concentrations of 5-FAM. The protein concentration of each tissue homogenate
was determined using the Bradford method and 5-FAM concentrations were
normalized to total protein in each sample. Total IDE activity in each sample was
calculated using the formula (Final Substrate Concentration – Initial Substrate
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Concentration / Time x Volume) x Dilution factor described by Kurauti et al. and
normalized to each samples total protein.
Hippocampus Synaptosome Preparation and Stimulation
Synaptosomal insulin responsiveness was evaluated by ex vivo
stimulation of isolated synaptosomal preparations as previously described
(Franklin & Taglialatela, 2016). Briefly, frozen WT and APP−/− mouse
hippocampi were homogenized using SynPER reagent (Thermo Scientific) with 1
% protease inhibitor cocktail and phosphatase inhibitor cocktail and centrifuged
at 1230 ×g for 10 min at 4°C. The supernatant was collected and centrifuged
once more at 15000 ×g for 20 min at 4°C. The pellet was resuspended in a
physiological buffer, HEPES-buffered Krebs-like HBK buffer (143-mM NaCl, 4.7mM KCl, 1.3-mM MgSO4, 1.2-mM CaCl2, 20-mM HEPES, 0.1-mM NaH2PO4,
and 10-mM D-glucose, pH 7.4) and aliquoted into tubes of equal protein for
unstimulated and insulin-stimulated samples. All tubes received 8 mM ATP and
insulin stimulation was performed with 10nM or 200nM of diluted U-100 insulin.
All tubes were incubated at 37 °C for 15 min. Samples were pelleted at 10000 ×g
for 10 min at 4°C and resuspended in 1× RIPA (75-mM NaCl, 25-mM Na2PO4,
1-mM EDTA, 0.5% NP-40, and 0.5% TritonX-100) plus 1% protease inhibitor
cocktail and phosphatase inhibitor cocktail. The bicinchoninic acid assay method
was used to prepare samples of equal protein concentration for WES capillary
Western blot technology (ProteinSimple). Data was collected using the area
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under peaks for the specified proteins and analysis performed using a Student’s
t-test.
Statistical Analysis
Statistical analysis was performed using SigmaPlot 12.0 software. Values
were averaged +/-SD and statistical significance was determined via one-way
ANOVA, two-way ANOVA or t-test, as appropriate. In the case of statistical
significance, the Turkey-Kramer post hoc test or Holm-Sidak multiple pair-wise
comparisons were used where applicable.
The difference in the mean relative IDE mRNA expression values for WT
and APP-/- was statistically analyzed by performing unpaired t-test with Welch
correction factor using GraphPad Prism 7.03 software (GraphPad Software, Inc.,
La Jolla, CA). P values less than 0.05 were considered statistically significant.
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CHAPTER III
RESULTS
Study 1 – Amyloid Precursor Protein in the Endocrine Pancreas
Introduction
Several lines of evidence indicate that metabolic dysfunction, insulin
resistance and perturbations in cerebral glucose utilization may play a critical role
in the disease process (Bedse, Di Domenico, Serviddio, & Cassano, 2015;
Biessels, Staekenborg, Brunner, Brayne, & Scheltens, 2006; De Felice &
Ferreira, 2014; de la Monte, 2014; Hoyer, 1991). Type 2 diabetes, or insulin
resistance, is reported to be a risk factor for developing dementia and evidence
suggests insulin signaling dysfunction occurs in the brains of AD patients (Crane
et al., 2013; Talbot et al., 2012).
One protein thought to be critical in the development of AD is Aβ, a selfaggregating peptide cleaved from the larger amyloid precursor protein (APP)
(Goldgaber, Lerman, McBride, Saffiotti, & Gajdusek, 1987; Selkoe et al., 1988).
APP is a single pass transmembrane protein of uncertain function highly
expressed in the CNS and detectable in many other cell types (Arai et al., 1991;
Konig et al., 1992; Schlossmacher et al., 1992). It is cleaved by proteases such
as beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and gamma
secretase to release N-terminal fragments (sAPPα and sAPPβ) and varying size
Aβ fragments (Aβ 1-40 and Aβ 1-42). Much of the research focused on APP
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biology has been in the context of Aβ plaque deposition in the central nervous
system. However, it is known that higher molecular weight isoforms of APP are
present in many peripheral organs (Selkoe et al., 1988). Our recent work has
focused on characterizing APP expression and function in several peripheral
tissues including intestinal and adipose tissue (Puig & Combs, 2013; Puig,
Floden, et al., 2012; Puig, Lutz, et al., 2015; Puig, Swigost, et al., 2012; Sondag
& Combs, 2010).
The pancreas has an essential role in the regulation of blood glucose
levels, primarily through the secretion of the hormone insulin from pancreatic
β cells. Pancreatic dysfunction is a well-known consequence of both type 1 and
type 2 diabetes (Ashcroft & Rorsman, 2012). Numerous studies in both primates
and mice suggest that damaging or stressing the endocrine pancreas may
promote changes in the central nervous system associated with the
pathogenesis of AD (Ho et al., 2004; Julien et al., 2010; Morales-Corraliza et al.,
2016; Takeda et al., 2010; X. Wang et al., 2010). Injections of insulin into a
transgenic mouse model of AD have been shown to improve the memory of
these mice as well as alter circulating concentrations of Aβ (Vandal et al., 2014).
Administration of insulin into the brain intranasally is being explored as a
cognitive enhancing therapeutic strategy in patients with AD (Claxton et al., 2015;
Holscher, 2014; Reger et al., 2008).
Like Alzheimer’s disease, diabetes has its own plaque pathology, in which
the self-aggregating peptide amylin, or IAPP, is co-secreted with insulin and
damages pancreatic islets (Lorenzo, Razzaboni, Weir, & Yankner, 1994;
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Westermark, Wilander, Westermark, & Johnson, 1987). Whether Aβ itself
influences pancreatic IAPP aggregation through cross-seeding, or injures islets
independently of IAPP remains uncertain. There are conflicting reports of the
detection of amyloid beta within human islets (Miklossy et al., 2010; Oskarsson et
al., 2015). Increased levels of Aβ or Aβ aggregates have been detected within
the pancreas of some transgenic mouse models of AD (Shoji et al., 1998; Shoji
et al., 2000; Vandal et al., 2015).
There is evidence that suggests that the endogenous functions of APP
may be linked to the regulation of insulin secretion and signaling or whole body
metabolism. The detection of APP has been reported in the exocrine and
endocrine pancreas by immunohistochemistry and in-situ hybridization,
respectively (Beer, Masters, & Beyreuther, 1995; Figueroa, Shi, Gardell, &
Austin, 2001). Additionally, a rigorous analysis of mice lacking APP (APP-/-)
and/or the related APLP2 gene shows changes in circulating blood glucose
concentrations (Needham et al., 2008). Another report has suggested APP may
directly regulate the process of insulin secretion from pancreatic islets (Tu et al.,
2012). In this study we examine murine and human pancreatic tissue to test the
hypothesis that APP or Aβ play a role in pancreatic function or pathophysiology
respectively.
APP was Expressed within the Endocrine Pancreas
To begin studying APP in the pancreas, we examined whole pancreatic
tissue collected from two month old wild type C57B6 (WT) , APP-/-, and
APP/PS1 mice. The APP-/- animals have the APP gene knocked out in all
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tissues. APP/PS1 mice overexpress both human APP and the γ-secretase
complex protein Presenilin-1 protein under the control of the prion promoter. This
leads to high transgene expression in the central nervous system and results in
Aβ plaque deposition in the brain with age. Pancreatic protein lysates were
resolved by 10% SDS-PAGE and immunoblotted to compare expression of APP
(Fig 1A). APP was detected in wild type pancreas, absent in APP-/- tissue, and
overexpressed in APP/PS1 mice. However, the human APP695 transgene
migrated at an apparent lower molecular weight than endogenous mouse APP,
consistent with reported expression of higher molecular weight isoforms in
peripheral tissues (Selkoe et al., 1988).
In order to determine which cell types were expressing APP,
immunohistochemistry was next performed. Pancreas from both two and twelve
month old WT, APP-/- and APP/PS1 mice was serial sectioned and stained using
antibodies against the c-terminus of APP (Fig 1B). Endogenous APP
immunoreactivity localized to both endocrine and exocrine pancreas, with clear
immunoreactivity in pancreatic islets at 12 months of age. APP immunoreactivity
in the APP/PS1 transgenic mice robustly localized to islets at either age.
Following our investigation of murine tissue, we determined whether human
pancreatic islets also expressed APP. Immunohistochemistry was performed on
healthy, type 2 diabetes, and cancerous human pancreatic tissue using
antibodies directed against the c-terminus of APP. Similar to the mouse tissue
findings, we observed clear APP immunoreactivity within the endocrine pancreas
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Figure 1.

Amyloid precursor protein was detected in mouse and human
pancreas including islets of Langerhans.
(A) Whole pancreas was collected from C57BL/6 (WT), APP-/-, and
APP/PS1 mice (n=7) and lysed in RIPA buffer. 20 µg of protein was
resolved by 10% SDS-PAGE and western blotted using anti-APP
(Y188) antibody or anti-GAPDH antibody as a loading control.
Normalized optical density was averaged +/- SD, *p<0.05.
(B) Pancreas was harvested from C57BL/6 (WT), APP/PS1, and
APP-/- at 2 months (n=7) and 12 months (n=4) of age. Tissue was
fixed in 4% paraformaldehyde and cryosectioned into 10 µm serial
sections. Immunohistochemistry was performed using anti-APP
(Y188) antibody. Vector VIP was used as the chromogen.
(C) Immunohistochemistry was performed on human pancreatic
tissue. Pancreas from a healthy 77 year old male donor, 68 year
old male type 2 diabetic donor and a 66 year old male with
pancreatic adenocarcinoma was probed using anti-APP antibody
(Y188) with vector VIP used as the chromogen.
(D) Representative western blot of protein lysates from cultured
pancreatic islets from WT, APP-/-, and APP/PS1 mice. Islet protein
was resolved by 10% SDS-PAGE, transferred to PVDF, and
immunoblotted using anti-APP antibody (Y188). Islets from a
healthy 55 year old male donor were cultured then lysed in RIPA
buffer and resolved using 10% SDS-PAGE then transferred to
PVDF membrane and western blotted using anti-APP antibody,
22C11.

41

42

of all three tissue types (Fig 1C). Pancreatic adenocarcinoma samples showed
particularly robust APP islet immunoreactivity (Fig 1C, Fig 2). This is in
agreement with a number of studies demonstrating upregulated APP in
pancreatic cancer where it may play a role in the disease process (Hansel et al.,
2003; Woods & Padmanabhan, 2013).

Figure 2.

APP immunoreactivity was increased in pancreatic
adenocarcinoma. Cryosections (10µm) from human healthy
pancreas and pancreatic adenocarcinoma were immunostained for
APP and insulin. Alexa Fluor 488 and 594 conjugated secondary
antibodies were used for visualization.
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The islet enriched APP immunoreactivity was validated by western blot
analysis from both murine and human islet cultures. Islets grown from WT, APP/-, and APP/PS1 mice demonstrated the expected increase in APP expression in
the APP/PS1 line with no detectable APP in the APP-/- mice (Fig 1D). Human
islet cultures also demonstrated robust APP levels via western blot analysis
(Fig 1D).
Pancreatic islets are primarily composed of insulin producing β cells. To
determine whether APP localized within these specialized cells we next
examined pancreas from the APP/PS1 mouse by immunofluorescence using
primary antibodies against APP and insulin. APP immunoreactivity was highly
localized to the insulin producing cells in the APP/PS1 mice (Fig 3A) Using the
same approach, we confirmed that APP localized to β cells of the human
pancreas (Fig 3B).
Pancreatic APP was Not Processed to Aβ
The presence of Aβ containing plaques has been reported in the pancreas
of some strains of transgenic mice although evidence of Aβ in human pancreas is
conflicting (Miklossy et al., 2010; Oskarsson et al., 2015). To determine whether
Aβ was present in our transgenic samples we utilized two methods, ELISA and
immunohistochemistry, to detect Aβ in mouse and human pancreas. Human Aβ
1-40 and 1-42 was quantified by ELISA from WT, APP-/- and APP/PS1
hippocampus, pancreas and primary islet culture lysates from twelve month old
animals (Fig 4A). Interestingly, while high concentrations of human Aβ were
detectable in the brain lysates of APP/PS1 transgenic animals, we did not detect
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Figure 3.

Amyloid precursor protein was detectable in the insulin producing
β cells of the human pancreas and the APP/PS1 mouse. Pancreatic
APP was not processed to Aβ. Immunofluorescent staining was
performed using (A) APP/PS1 transgenic mouse and (B) human
tissue cryosections (10µm). Anti-APP (Y188) and insulin primary
antibodies with Alexa Flour 488 and Alexa Flour 594 fluorophore
conjugated secondary antibodies were used for visualization with
DAPI counterstain.
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Figure 4.

Aβ was not detectable in mouse pancreas by
immunohistochemistry or ELISA.
(A) Mouse pancreas and hippocampus tissue was lysed in RIPA
buffer (n=4/strain), while islets (n=6/strain) were pelleted and lysed
in Triton X-100 buffer to yield detergent soluble Aβ extract. Extract
was used to quantify both human Aβ 1-40 and human Aβ 1-42 by
ELISA. APP-/- animals served as a negative control to measure the
background of the assay. Data is expressed as mean values +/-SD,
*p<0.05 from WT.
(B) Immunohistochemistry was performed on 10µm cryosections of
WT, APP-/-, and APP/PS1 murine pancreas as well as human
healthy control, type 2 diabetes (T2D), and adenocarcinoma
pancreas tissue. Anti-Aβ antibody (4G8) was used with Vector VIP
as the chromogen.
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a significant increase in Aβ in the pancreas or islet lysate of these animals.
Taken together, these data suggest that APP is processed by alternative
mechanisms in the pancreas as compared to brain.
To further investigate the possibility of pancreatic Aβ production, we
utilized immunohistochemistry to stain for Aβ. Since we and others have
previously observed that the APP/PS1 line accumulates brain Aβ deposits in an
age dependent manner (Gordon et al., 2002; Manocha et al., 2016), WT and
transgenic mouse pancreas were immunostained to detect Aβ at two and twelve
months of age (Fig 4B). A faint amount of immunoreactivity was observed in
12 month old APP/PS1 islets relative to the APP-/- and WT mice likely due to the
anti-Aβ antibody, 4G8, cross-reacting with full length APP. However, there were
clearly no distinct signs of Aβ plaque deposition in either the two or twelve month
old mouse pancreas. We also examined healthy, type 2 diabetes, and
adenocarcinoma human pancreas tissue for Aβ immunoreactivity as well as for
nonspecific amyloids by thioflavin staining (Fig 4B, Fig 5). While thioflavin S
stained several areas of both healthy and type two diabetic pancreas, no
detectable Aβ plaque-like deposits were observed although some scattered
puncta which may correspond to Aβ or sAPP were noted in all conditions,
including within pancreatic islets. Following these negative results, we sought to
determine if the methodology we employed was sufficient to detect amyloid
deposits. We performed immunostaining for Aβ in addition to thioflavin S staining
in 12 month WT and APP/PS1 mouse brain tissue sections (Fig 5). As expected,
APP/PS1 brains showed abundant plaque deposition using both methods without
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detectable plaques in WT brains (Fig 5) in contrast to a clear lack of any plaquelike deposits in the pancreas (Fig 4B).

Figure 5.

Thioflavin staining and Aβ immunohistochemistry in human
pancreatic tissue and mouse brains. Cryosections (10µm) of
healthy human pancreas and type 2 diabetic pancreas or WT and
APP/PS1 brain tissue sections (40 µm) were immunostained for Aβ
or stained with thioflavin S. Vector VIP was used as the
chromogen.
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APP/PS1 Mice Showed no Differences in Glucose Tolerance Testing or
Pancreatic Insulin Levels but had Significantly Decreased
Pancreatic Glucagon Compared to WT and APP-/- Mice.
An essential function of the pancreas is to regulate blood glucose levels.
In order to test if differences in pancreatic islet APP content caused changes in
whole body glucose tolerance we subjected WT and transgenic animals to 2g/kg
glucose challenge by oral gavage. Blood glucose measurements were taken
from tail clipping after four hours of fasting and at 15, 30, 60 and 120 minutes
after glucose challenge (Fig 6A, B). Surprisingly, no differences were observed
across genotypes. In addition to assessing glucose tolerance, we also
homogenized whole pancreas from 2 month old animals and assessed their
insulin and glucagon content by ELISA (Fig 6C, D). Glucagon concentrations
from APP/PS1 pancreas were significantly lower than WT and APP-/- mice
although no changes in insulin content were detected across genotypes. Based
upon the glucagon differences, APP/PS1 pancreas tissue was fluorescently
double labeled with anti-APP and glucagon antibodies. Although there were
relatively few glucagon immunoreactive cells it was clear that they colocalized
with APP immunoreactivity suggesting that transgene expression alters the
biology of these cells (Fig 7).
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Figure 6.

No difference in glucose tolerance or pancreatic insulin content was
observed in APP-/- and APP/PS1 mice, but whole pancreas
glucagon content was reduced in APP/PS1 mice. 2 month old WT,
APP-/-, and APP/PS1 mice were subjected to glucose tolerance
testing. Prior to testing, mice were fasted four hours and then
received 2g/kg glucose by oral gavage.
(A) Blood glucose was measured at intervals by blood glucose
meter (n=4-7).
(B) The area under the curve (AUC) from glucose tolerance testing
of each mouse was measured and the results from each strain are
graphed. Each strain was normalized to the mean AUC of the WT
strain. Whole mouse pancreas was lysed using RIPA buffer.
(C) Insulin (n=6-7) and
(D) glucagon (n=6-7) content were assessed by ELISA. Data is
shown as mean values +/-SD, *p<0.05.
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Figure 7.

APP was present in glucagon producing cells in the APP/PS1
mouse. Cryosections (10µm) of APP/PS1 mouse pancreas were
immunostained for APP and glucagon. Alexa Fluor 488 and 594
conjugated secondary antibodies were used for visualization.

APP Expression Modulated Pancreatic BACE2, GLUT4, and IDE
Levels in the Transgenic Mice.
To better understand the contribution of APP expression to pancreatic
physiology, we quantified protein levels from homogenized murine pancreas of
WT and transgenic animals by western blot with a particular focus on proteins
involved in insulin signaling, glucose uptake and Aβ degradation (Fig 8).
Although no changes in protein levels of the glucose transporters GLUT1,
GLUT2, or GLUT3 were observed across genotypes, protein levels of GLUT4
were significantly elevated in APP-/- mice compared to WT, and APP/PS1 mice.
No differences in insulin receptor (IR), pAkt or pGSK3β levels were observed.
Similarly, total protein levels of zinc transporter 8 (ZNT8) did not differ across
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Figure 8.

Differences in 2 month old mouse pancreatic BACE2, IDE and
GLUT4 were observed by western blot. Whole pancreas from WT,
APP-/-, and APP/PS1 mice was lysed in RIPA buffer and resolved
using 10% SDS-PAGE. Protein was transferred to PVDF
membrane and western blotted for multiple proteins using GAPDH
as a loading control. Optical density was measured and normalized
to mean WT optical density (n=7). Data is expressed as mean
values +/-SD, *p<0.05.

species. BACE2 has been suggested to both interact with APP in vitro as an αsecretase and play a role in pancreatic insulin secretion through the cleavage of
its substrate, TMEM27 (Esterhazy et al., 2011; Yan, Munzner, Shuck, &
Bienkowski, 2001). We assessed BACE2 protein levels using an antibody
against an amino acid sequence within the prodomain of BACE2 that is not found
in BACE1 (B. D. Bennett et al., 2000). Strikingly, total protein levels of BACE2
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were significantly reduced in APP-/- and APP/PS1 compared to WT indicating
that APP may influence the expression or activity of BACE2 in the pancreas.
Since both Aβ and insulin are degraded by a common enzyme, insulin degrading
enzyme (IDE) (Qiu et al., 1998), we quantified IDE protein levels to observe a
significant increase in APP-/- mice compared to all other genotypes. We also
quantified protein levels of another Aß degrading enzyme, neprilysin, but
detected no differences across genotypes. This suggested that APP has a role in
regulating the expression of GLUT4, IDE and BACE2 in the pancreas.
BACE2 Immunoreactivity was Localized to Islet Periphery
with Decreased Immunoreactivity in APP/PS1 Mice With
no Concomitant Increase in Aβ Immunoreactivity.
Following our observation of changes in pancreatic BACE2 and IDE
protein levels, we performed immunohistochemistry on 2 month old WT and
transgenic mouse pancreatic serial sections to determine where changes in
protein expression localized (Fig 9A). Increased immunoreactivity for IDE was
observed in APP-/- tissue, with the higher levels of IDE observed in the acinar
tissue of the pancreas. Immunohistochemistry for BACE2 using antibodies
directed against the N-terminal prosequence revealed BACE2 expression within
the endocrine pancreas, with the highest levels of immunoreactivity at the
periphery of islets. In agreement with the western blots, BACE2 immunoreactivity
was notably less robust in APP/PS1 mice compared to WT. To validate this
pattern of BACE2 tissue expression and further investigate APP processing
within pancreatic islets, we performed immunohistochemistry on 12 month old
WT and transgenic mouse pancreas sections using primary antibodies against
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BACE2, IAPP, CD68, Aβ Glucagon (Fig 9B, Fig 10) Immunohistochemistry for
BACE2 revealed a similar pattern of protein expression at 12 months of age as
was observed at 2 months, with the highest levels of BACE2 detected at the
periphery of the islets. We further validated our BACE2 immunohistochemistry
results by performed peptide blocking studies in mouse tissue to demonstrate the
specificity of the BACE2 islet staining (Fig 10). Antibody pre-incubation with the
BACE2 epitope blocking peptide completely abolished islet BACE2 staining at
the islet periphery demonstrating our immunohistochemistry results are specific

Figure 9.

Immunohistochemistry of 2 and 12 month old mouse pancreas.
(A) Immunohistochemistry was performed on WT, APP-/-, and
APP/PS1 mouse 2 month old 10µm pancreas cryosections using
primary antibodies against IDE and BACE2 (n=7). Tissue was fixed
with 4% paraformaldehyde and Vector VIP chromogen was used as
the chromogen. (B) Immunohistochemistry was performed on
12 month old murine 10µm pancreas cryosections (n=4). Primary
antibodies against amylin/IAPP, BACE2, CD68, Aβ oligomers
(MOAB-2) and Aβ were utilized to detect proteins. Vector VIP was
used as the chromogen.
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Figure 10.

BACE2 immunohistochemistry with epitope blocking peptide
control and glucagon immunohistochemistry with optical density
quantitation in mouse tissue.
(A) Cryosections (10µm) of WT and transgenic mouse pancreas
were immunostained for BACE2 in the presence or absence of a
BACE2 epitope blocking peptide. Vector VIP was used as the
chromogen. Densitometric analysis of BACE2 islet immunostaining
was conducted in 12 month old mice (n=8). Staining intensity
values were normalized to WT levels and averaged +/-SD, *p<0.05.
(B) Cryosections (10µm) of WT and transgenic mouse pancreas
were immunostained for glucagon with Vector VIP as the
chromogen. Densitometric analysis of glucagon islet
immunostaining was conducted in 12 month old mice (n=5-6).
Staining intensity values were normalized to WT levels and
averaged +/-SD, *p<0.05.
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to the BACE2 epitope. We also quantified the intensity of BACE2 and glucagon
immunoreactivity in mouse islets and observed significantly less BACE2 and
glucagon staining in APP/PS1 mouse islets (Fig 10). No differences in
IAPP/amylin aggregation were observed across mouse genotypes, which is as
expected as mouse amylin is not known to form amyloid plaques. No Aβ plaquelike structures were detectable using antibodies against monomeric or oligomeric
Aβ. Staining with anti-CD68 antibody to detect macrophages did not reveal any
differences in islet macrophage infiltration suggesting local overexpression of
APP within islets did not result in local Aβ-mediated immune activation as is
known to occur in the central nervous system (Dhawan, Floden, & Combs, 2012;
Jimenez et al., 2008). As expected, mouse glucagon was localized primarily at
the islet periphery.
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Immunohistochemistry for BACE2 Demonstrated Differential
BACE2 Localization in α and β Cells in Both
Mouse and Human Tissue.
To determine the identity of the pancreatic islet cells stained positive for
BACE2, we performed immunofluorescent double labeling of tissue from WT 2
month old animals for BACE2 and either insulin or glucagon (Fig 11).
Surprisingly, BACE2 immunoreactivity was highest in cells staining positive for
glucagon suggesting BACE2 may be differentially active or expressed in
pancreatic α compared to β cells. The staining of α cells at the periphery of the
islet is consistent with the known anatomical organization of murine pancreatic
islets of Langerhans (Cabrera et al., 2006). Using this approach, we stained WT,
APP-/-, and APP/PS1 mouse pancreas for both BACE2 and insulin, and obtained
complimentary results indicating the BACE2 enzyme localized within the islets
and was more highly immunoreactive outside the insulin producing cells at the
periphery of the islets (Fig 12). We then co-labeled human pancreatic tissue for
BACE2 and glucagon in the absence or presence of the BACE2 epitope blocking
peptide to determine if BACE2 was also present in human α cells (Fig 11).
Interestingly, we again observed robust BACE2 immunoreactivity in glucagon
positive cells, indicating this pattern of BACE2 expression is conserved across
mouse and human α cells. Pre-incubation with the BACE2 epitope blocking
peptide eliminated BACE2 immunoreactivity in α cells, indicating this antibody
staining was specific to the BACE2 protein epitope.
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Figure 11.

BACE2 was present in glucagon positive cells.
Immunohistochemistry was performed on (A) WT mouse and (B)
human 10µm pancreas cryosections using antibodies against
BACE2 and insulin or glucagon with or without pre-incubation with
BACE2 epitope blocking peptide. Fluorescent secondary antibodies
were used for visualization (anti-rabbit Alexa-Fluor 488 and antimouse Alexa Fluor 594). DAPI staining was used to visualize cell
nuclei.

Figure 12.

BACE2 immunoreactivity in wild type and transgenic mouse islets.
Cryosections (10µm) of WT and transgenic mouse pancreas were
immunostained for BACE2 and insulin. Alexa Fluor 488 and 594
conjugated secondary antibodies were used for visualization with a
DAPI counterstain.
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Primary Murine Islet Cultures Showed Significant Differences
in APP and IDE Content.
Only a small fraction of the pancreas is composed of hormone secreting
endocrine cells. To determine if protein differences observed in the whole
pancreas lysate were due in part to differences in pancreatic islets, we cultured
pancreatic islets isolated from WT, APP-/-, and APP/PS1 animals. We cultured
these islets for 24 hours and selected healthy islets of similar size for lysing and
western blot analysis (Fig 13). We examined islet lysate for differences in APP,
IDE, GLUT4 and BACE2 as differences in the levels of these proteins were
observed in whole pancreas lysate. GAPDH was utilized as a loading control. As
expected, APP was not detectable in APP-/- islets while APP/PS1 islets had high
levels of APP. Surprisingly, like our whole pancreas extracts, IDE was
significantly increased in APP-/- islets compared to WT. We were unable to
detect GLUT4 in islet lysates. Islet BACE2 protein levels were not significantly
different in transgenic animals compared to wild type controls, in contrast to our
immunostaining results. One possibility for this discrepancy is perhaps due to
loss of peripheral islet cell integrity during the isolation or culture conditions we
employed suggesting that further optimization is required in future work.
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Figure 13.

Western blots of 12 month old mouse primary islet cultures. WT,
APP-/-, and APP/PS1 pancreatic islets (n=3) were cultured
overnight and the next day 50 islets from each animal were
selected, pelleted, and lysed in RIPA buffer. Protein lysate was
resolved by 10% SDS-PAGE then transferred to PVDF membranes
and western blotted with antibodies against APP (Y188), IDE,
GLUT4, and BACE2. Anti-GAPDH was used as a loading control.
Optical density was measured for IDE and BACE2 and was
normalized to WT optical density. Data is expressed as mean
values +/-SD, *p<0.05.
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APP was Processed by α-secretase Activity in Primary
Islet Cultures and Recombinant sAPP Potentiated Islet Insulin
but not Glucagon Secretion.
The presence of BACE2, as well as the lack of detectable Aβ, suggested
that pancreatic APP was processed by a non-amyloidgenic pathway. It is known
that sAPP is detectable in the conditioned media of cell cultures from a number
of cell types (Weidemann et al., 1989). To determine if processing of pancreatic
APP resulted in the release of sAPP into conditioned media, we grew primary
cultures of both mouse and human pancreatic islets and collected the cells and
conditioned media after 24 hours for western blot analysis (Fig 14A). Both murine
and human mutant APP were processed through the α-secretase pathway
resulting in the release of sAPP into culture media, including the human mutant
APP expressed in APP/PS1 islets. Human sAPPα from APP/PS1 islets was
detected using the 6E10 monoclonal antibody, which is has been demonstrated
to bind human sAPPα (Bailey et al., 2008).
To better understand whether secreted sAPPα may have autocrine
effects, we assessed insulin and glucagon secretion from primary cultures of
isolated islets. A glucose stimulated insulin secretion (GSIS) assay demonstrated
significantly attenuated insulin secretion from APP-/- islets compared to WT and
APP/PS1 while APP/PS1 islets had significantly higher insulin secretion
compared to both WT and APP-/- cultures (Fig 14B). In order to determine
whether the differences in insulin secretion could be related to sAPPα, WT islet
cultures were stimulated with recombinant sAPPα during the GSIS assay.
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Figure 14.

sAPP was released from primary murine and human islet cultures
and recombinant sAPPα potentiated islet insulin secretion during
glucose stimulated insulin secretion assay.
(A) Primary islet cultures from WT, APP-/-, and APP/PS1 mice
were grown for 24 hours. Conditioned media was collected and
protein content was assessed by western blot using antibodies
against N-terminal APP. 22C11 detects both mouse and human
APP while 6E10 is specific to human APP and detects sAPPα.
Human islets were cultured for 24 hours and both conditioned
media collected for analysis by western blot using anti N-terminal
APP antibody (22C11).
(B) Primary cultures of mouse islets were assessed for differences
in insulin and glucagon secretion at 5mM glucose. Wild type islets
were stimulated with 10 nM recombinant human sAPPα and
supernatant was collected for insulin (n=8) and glucagon (n=4)
ELISA. Insulin secretion data from multiple sAPP stimulation
experiments were pooled by normalizing to the mean of the
unstimulated control from each experiment.
(C) The MIN6 insulin secreting cell line was grown as pseudo-islets
and was stimulated with 0, 1nM, or 10nM recombinant sAPPα in
GSIS assay at either 3.7mM or 16.7 mM glucose (n=6-8/condition).
Data is expressed as the mean +/- SD, *p<0.05.
(D) Human islets were treated with 10 nM recombinant sAPPα
during the GSIS assay in 3.7, 10, and 16.7 mM glucose. After one
hour of treatment, islet insulin secreted into the supernatant was
assessed by ELISA. Data was pooled from five donors and
normalized to basal insulin secretion at 3.7 mM. Data is expressed
as the mean +/- SD, *p<0.05. 1µM forskolin was used with 16.7 mM
glucose to potentiate insulin secretion as a positive control.
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In these studies, we utilized 10 nM sAPPα for stimulations as this concentration
has been shown to initiate signaling events in neuronal cells and is above the
estimated EC50 of 2.3nM (Jimenez et al., 2011). Stimulation with sAPPα
resulted in a significant but modest potentiation of islet insulin but not glucagon
secretion (Fig 14B).
This suggested that differences in basal insulin secretion from primary
cultures of islets across genotype may be due, in part, to autocrine stimulation
with sAPPα. It also suggests that sAPPα has a role particularly in insulin biology
of pancreatic islets or may support islet phenotype and survival in vitro.
Following our observation that sAPPα potentiates insulin secretion in
cultures of primary mouse islets, we sought to further validate this finding by
utilizing the MIN6 mouse β-cell line to test the effect of different doses of sAPPα
and different concentrations of glucose on insulin secretion from MIN6
pseudoislets (Fig 14C). Similar to our primary islet cultures, we observed that
treatment with sAPPα modestly but significantly potentiated insulin secretion from
MIN6 pseudoislets at 16.7mM glucose concentration. This effect was dose
dependent, with 10 nM but not 1 nM recombinant sAPPα having a significant
effect.
In order to further validate the findings from the mouse islets and MIN6
cells, we performed similar GSIS assays on human donor islets. Treatment of
human islets with 10 nM recombinant sAPPα during GSIS assays demonstrated
a significant potentiation of insulin secretion using a range of glucose
concentrations (Fig 14D).
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CHAPTER IV
RESULTS
Study 2 – Amyloid Precursor Protein and Insulin Degrading Enzyme
Introduction
Mounting evidence suggests that perturbations in brain metabolism and
insulin signaling play a role in the pathology of Alzheimer’s disease (AD) (Harris
et al., 2016; Hoyer, 1991; Macauley et al., 2015; Mosconi et al., 2006; Talbot et
al., 2012) Histologically, AD is characterized in part by the robust accumulation of
extracellular “plaque” aggregates of the Aβ peptide in central nervous system
(Selkoe & Hardy, 2016). Aβ is generated in the brain by the enzymatic cleavage
of the much larger Amyloid precursor protein (APP). Amyloid precursor protein or
APP is a transmembrane glycoprotein encoded on the 21st chromosome in
humans (Blanquet et al., 1987; Robakis et al., 1987). APP is part of a three
member family of proteins which also includes APLP1 and APLP2 (U. C. Muller &
Zheng, 2012). While expression of APLP1 is largely restricted to the central
nervous system, both APP and APLP2 are expressed ubiquitously and can be
detected in a variety tissues (Lorent et al., 1995). Of this protein family, only APP
generates the Aβ peptide. Interestingly, the APP family of proteins seems to be
required for life, or is at least critical for normal animal development. Knockout of
APP and APLP2 genes in mice has been shown to be postnatally lethal, as is
knockout of both APLP1 and APLP2 (Heber et al., 2000). Deletion of just the
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APP gene confers a more benign phenotype, including reduced animal body
weight and organ size, changes in grip strength and broad changes in
metabolism (Puig et al., 2017; Zheng et al., 1995). Mouse knockouts of APLP1
have also been studied and show similar reductions in animal body weight
(Heber et al., 2000). The APP gene is widely conserved among other species,
suggesting it performs important or advantageous biological functions (Tharp &
Sarkar, 2013).
Despite the known phenotypic changes in APP-/- mice, the physiologic
function(s) of APP is less certain. However, over the last three decades
numerous studies have investigated the APP family and much is now known.
The structures of APP, APLP1 and APLP2 are similar (U. C. Muller & Zheng,
2012). All three proteins are membrane spanning with a small intracellular
domain and a large n-terminal ectodomain. The mature proteins are processed
similarly by proteases, resulting in the release of soluble extracellular domain
APP/APLP fragments termed sAPP and sAPLPs (Walsh et al., 2007). Research
on the APP family of proteins highlights their importance, particularly in the
central nervous system. The APP family of proteins have been characterized as
synaptic adhesion molecules and upregulated during synaptogenesis (Schilling
et al., 2017). Furthermore, the full length APP protein itself is believed to be
involved in certain signaling processes and may function as a cell surface
receptor for extracellular ligands (Hass & Yankner, 2005). It has also been
reported that APP and its metabolites play a role in neurite outgrowth and
neuronal migration (Gakhar-Koppole et al., 2008). Taken together, these studies
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suggest APP and its metabolites can influence a variety of cellular processes and
may be particularly important in the CNS and at the synapse.
In our other work, we observed higher levels of insulin degrading enzyme
(IDE) protein in pancreatic tissue derived from APP-/- animals compared to
control animals (Kulas, Puig, & Combs, 2017). IDE is a zinc metalloprotease
widely recognized for its role in hydrolyzing insulin in addition to numerous other
substrates including the plaque forming peptides Aβ and pancreatic amylin or
IAPP (Kurochkin et al., 2018). In this study we sought to expand on this
observation and have examined the APP-/- mice to test the hypothesis that
deletion of the APP gene alters the protein levels of IDE.
IDE Protein and mRNA are Increased in APP-/- Tissues
We began examining the role of APP in regulating IDE by collecting liver
tissue from two month old female C57BL/6 and APP-/- mice. This tissue was
chosen in particular because of the physiologic importance of insulin signaling in
regulating liver gluconeogenesis and glycogenolysis. The transgenic APP
knockout mouse has the APP gene knocked out in all tissues via deletion of the
promoter region and first exon. Mouse liver was homogenized on ice and protein
content was assessed by western blot. (Fig 15A). Interestingly, IDE protein levels
were found to be significantly increased in APP-/- muscle (n=7, P<0.023)
compared to controls. Next, we examined muscle tissue collected from WT and
APP-/- animals (Fig 15B). Like in liver, we observed increased IDE protein
content in liver tissue
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Figure 15.

IDE is increased in APP-/- tissues.
(A-C) IDE protein was measured in liver (n=7), gastrocnemius
muscle (n=6) and hippocampus tissue (n=6-7) by western blot and
normalized to GAPDH as a loading control.
(D) IDE mRNA levels were measured in hippocampus extracts
(n=4-5) and normalized to ribosomal 16S RNA as a loading control.
Statistical significance p<0.05* was determined by students t-test.
(E) Immunohistochemistry for IDE protein was performed on WT
and APP-/- brain tissue sections (n=4-6). Data is graphed as ±
SEM.
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extracts from APP-/- mice compared to WT controls (n=7, p=0.001). These data,
along with our previous observations of elevated IDE protein in pancreatic
extracts from APP-/- mice, suggested to us that APP negatively regulates IDE
levels in numerous peripheral tissues.
It has been suggested that IDE degrades a number of small
amyloidogenic peptides, including Aβ, which may in turn have important
implications in the pathogenesis of Alzheimer’s Disease. Because of this
seemingly important role of IDE in peptide clearance, we next sought to examine
if ablation of the APP gene altered IDE protein levels in the CNS. Because the
hippocampus serves a critical role in memory and is damaged early in the
progression of AD, we collected hippocampus tissue from WT and APP-/- brain
hemispheres and extracted protein for western blot (n=6-7). As expected, APP
was not detectable in APP-/- brain tissue homogenate (Fig 15C). Surprisingly,
IDE protein levels were found to be significantly increased and almost three fold
higher in APP-/- hippocampus tissues compared to WT controls (p<0.001). This
suggested that APP regulation of IDE extends to the central nervous system. We
then examined mRNA levels to determine if APP is regulating IDE at the level of
transcription or if it is a post-translational phenomenon. RNA was extracted from
WT and APP-/- hippocampus tissues and converted to cDNA and the relative
abundance of IDE transcripts were determined relative to 18s ribosomal RNA
(n=4/5). Interestingly, we observed a significantly increased abundance of IDE
mRNA in APP-/- hippocampus tissue compared to WT controls (p=0.002)
(Fig 15D). Similar to protein levels of IDE, we observed a greater than 3 fold
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average increase in IDE expression in APP-/- hippocampus tissue compared to
WT controls. To gain a greater understanding of which cell types may be most
abundantly expressing IDE, we performed immunohistochemistry to detect IDE in
WT and APP-/- brain tissue. IDE was detectable throughout the brain including in
white matter. Neurons within the hippocampus were stained to a greater extent
than other cell types, though IDE immunostaining did not robustly label a single
cell type compared to others in the CNS (Fig 15E). Collectively these data
suggested that APP acts as a negative regulator of IDE levels and that ablation
of APP increases IDE at the level of transcription. IDE is produced throughout the
brain and across many cell types.
IDE Protein is Increased in APP-/- Neuron, Astrocyte
and Microglia Cell Cultures. siRNA Knockdown of APP
in Microglia Increases IDE.
Following our observation that IDE mRNA and protein levels are robustly
increased in the hippocampus tissue of APP-/- mice, we next sought to
determine which cell type(s) found in the brain are responsible for increased IDE
content. We began by culturing embryonic day 16 neurons from WT and APP-/mouse embryos (Fig 16A). As expected, APP was abundant in WT neurons and
not detectable in APP-/- cultures. Consistent with our observations in whole
tissues, IDE protein levels were significantly increased in APP-/- neuronal
cultures compared to WT controls (n=4, p<0.010). Unlike neurons, astrocytes
and microglia, two other abundant cell types found in the CNS, produce a higher
molecular weight isoform of APP which may have functional consequences for
APP biology. Astrocytes are the most abundant cell type found in the CNS and
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Figure 16.

IDE is increased in APP-/- cell cultures.
(A-C) Primary cell cultures of neurons (n=4), astrocytes (n=3), and
microglia from WT, APP-/- and the APP/PS1 mouse model of AD
were grown and assessed for IDE protein content by western blot
with GAPDH as a loading control. Significance p<0.05* was
determined by students t-test.
(D) Cultures of SIM-A9 mouse microglia cells (n=6/condition) were
treated with either scrambled siRNA or anti-APP siRNA for one
week. After treatment, total cell protein content was assessed by
western blot with α-tubulin as a loading control. Significance
p<0.05* was determined by students t-test. Data is graphed as ±
SEM.
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play an important role in brain metabolism among many other functions. Thus,
we cultured astrocytes and microglia to examine if APP regulates IDE protein in
these glial cell types in a manner similar to neurons (n=3/condition). We
observed that APP migrated at higher molecular weight in astrocytes relative to
neurons, consistent with known higher molecular weight isoforms of APP in these
cells (Figure 16B). IDE protein levels were found to be significantly increased in
both astrocyte (p=0.009) and microglia (Figure 16C, p=0.009) cultures relative to
WT controls. This data suggested APP regulates IDE in both neuron and glia and
that APP regulation of IDE is not specific to the isoform of APP expressed in
diverse cell types. Furthermore, this suggests that multiple cell types are
responsible for increased total IDE levels found in APP-/- hippocampus extracts.
Given that we observed increased IDE in APP-/- microglia, and that
microglial IDE may be particularly important for degrading Aβ, we next tested the
hypothesis that knockdown of APP with siRNA in the SIMA9 microglial cell line
will increase IDE levels in vitro (Figure 16D). Knockdown of APP protein was
performed over 1 week with either an anti-APP siRNA pool or a scrambled siRNA
control (n=6/condition). As expected, treatment with anti-APP siRNA significantly
reduced APP as measured by western blot. (p=0.003). Surprisingly, IDE protein
levels were robustly and significantly increased in microglia (p<0.001) treated
with anti-APP siRNA, suggesting that knockdown of APP in vitro is sufficient to
increase IDE protein levels in cultured cells. This also suggests that APP has a
direct role in regulating IDE and the increased levels of IDE observed in the
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APP-/- mouse may not be a consequence of general differences in the
physiology of the animals.
IDE Activity is Increased in APP-/- Tissues
While numerous APP-/- mice tissues had increased IDE content
compared to WT controls, we next examined if the enzymatic activity of IDE was
also increased in APP-/- mouse tissues. To measure IDE activity, we utilized a
commercially available IDE activity assay. This assay utilizes a FRET peptide
IDE substrate that emits increased 5-FAM fluorescence when hydrolyzed by the
IDE enzyme. Hippocampus tissue, gastrocnemius muscle and liver tissue were
collected from 2 month old WT and APP-/- mice (n=6 condition) and
homogenized. Each tissue homogenate was then mixed with the IDE substrate
and fluorescence was measured over time (Fig 17). The IDE activity of each
tissue extract was calculated and normalized to the total protein content of the
sample. Significantly increased IDE activity was observed in APP-/- hippocampus
(p=0.016) and liver extracts (p=0.003), indicating that increased IDE protein
content in these tissues leads to functional differences in IDE activity. Unlike
hippocampus and liver tissue, no significant differences in IDE activity were
observed between WT and APP-/- gastrocnemius muscle tissue extracts.
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Figure 17.

IDE activity is increased in APP-/- tissues. WT and APP-/- tissues
(n=6) were harvested on ice and rapidly assayed for IDE activity
over the course of 1 hour. The IDE activity assay uses a FRET
peptide which is liberated from a quencher and exhibits increased
fluorescence when cleaved by IDE. Relative fluorescent units are
converted to concentrations of FAM via standard curve. The data is
normalized to the amount of total protein collected from each
tissue. IDE activity was calculated from each animal tissue and
significance p<0.05* was determined by students t-test. Data is
graphed as ± SEM.
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Insulin Content and Insulin Signaling are Altered in
APP-/- Hippocampus tissue and Synaptosomes
We next sought to probe for consequences of increased IDE protein
content and enzyme activity on insulin levels and insulin signaling markers in
hippocampus tissue. We measured the insulin content of 2 month old WT and
APP-/- hippocampus extracts by ELISA (n=11/13) and normalized to total protein
(Fig 18A). Hippocampus extracts from APP-/- mouse had significantly reduced
hippocampal insulin content compared to WT animals (p=0.032), suggesting that
insulin content of the brain may be reduced in these animals. Following this
observation, we next examined hippocampus extracts from WT and APP-/- mice
for changes in insulin signaling markers. While we were unable to clearly detect
phosphorylated insulin receptor in these lysates (Fig 18B), we also examined
markers of insulin signaling downstream of the receptor which serve as a positive
indicator of insulin signaling. We observed significantly reduced (p=0.025) levels
of pAKT S308 in APP-/- hippocampal lysates compared to WT controls,
suggesting that APP-/- animals have diminished or impaired insulin signaling in
brain tissue.
To further examine insulin signaling in the brains of these animals, we
prepared synaptosomes from WT and APP-/- tissues and stimulated them
acutely with insulin ex vivo. Stimulated synaptosome lysate was then analyzed
for protein and phosphor protein content by WES capillary western blot. We have
previously utilized this method to examine insulin signaling in the brains of other
transgenic mice (Puig et al., 2016) and the details of this method have been
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Figure 18.

Insulin signaling and content are altered in the APP-/- brain.
(A) Total hippocampal insulin content was measured in RIPA
extractions of WT and APP-/- hippocampus tissue by ELISA. (n=13)
(B) Insulin signaling cascade markers were assessed in two-month
old WT and APP-/- hippocampal tissue. (n=5-6/condition)
(C) Hippocampal synaptosomes from 2 month old WT and APP-/animals were prepared and stimulated with 10 nM insulin (n=5/5) or
200 nM insulin (n=6/4) pIR, total IR and β tubulin protein levels
were measured using the WES system. Data was collected using
the area under peaks for the specified proteins and analysis
performed using a Student’s t-test with significance p<0.05*.
Data is graphed as ± SEM.
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expanded on in recent literature (Franklin & Taglialatela, 2016). WT and APP-/synaptosomes were stimulated with either 10 or 200 nM insulin (n=4-6/condition).
Interestingly, APP-/- synaptosomes showed diminished phosphorylation of the
insulin receptor compared to WT synaptosomes when stimulated with either 10
nM (p=0.0315) or 200 nM (p=0.0265) insulin. (Fig 18C). No differences in the
ratio of phosphorylated IR to IR were observed in the unstimulated
synaptosomes. These data suggest that APP-/- animals have impaired insulin
signaling in the brain at the level of the insulin receptor.
Aged APP-/- Mice Display Fasting Hypoglycemia
Without Changes in Glucose Tolerance.
While our data suggests APP-/- animals have changes in brain insulin
signaling, the potential effects of elevated peripheral IDE on metabolic
homeostasis remains uncertain. To determine if APP-/- animals have abnormal
glucose homeostasis we performed glucose tolerance testing on 12 month WT
and APP-/- (n=11-13/condition). Animals were fasted for 5 hours on the day of
the experiment and then administered 2g/kg body weight glucose by
intraperitoneal injection. Blood glucose was monitored by glucometer just prior to
injection and at 15, 30, 60 and 120 minutes after injection. Data was graphed as
blood glucose versus time and the area under the curve was assessed (Fig 19).
No significant difference was observed in overall glucose tolerance (p=0.12)
between WT and APP-/- animals. However, we did observe a robust and
significant reduction in the fasting blood glucose levels of APP-/- animals
(p=0.002) compared to WT controls. Blood glucose was also measured in free
fed WT and APP-/- mice (n=5/condition) and was not significantly different
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(p=0.221). These data suggest APP-/- animals are glucose tolerant but have
metabolic abnormalities when fasted.

Figure 19.

Aged APP-/- animals show metabolic changes. WT and APP-/animals (n=11-13) were fasted and subjected to glucose tolerance
testing with IP injections glucose. Area under the curve (AUC) was
measured for each animal’s blood glucose over time, and WT and
APP-/- animals were compared by t-test with p<0.05*. Blood
glucose was measured and graphed in fasted or in free fed (n=5)
WT and APP-/- mice. Significance p<0.05* was determined by
students t-test. Data is graphed as ± SEM.
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Overexpression of APP or Treatment with Secretase
Inhibitors Does Not Alter IDE Levels.
APP is cleaved by a variety of enzymes termed secretases which result in
the production of various APP fragments. To examine if inhibition of secretases
through selective inhibitors is sufficient to alter levels of IDE, SIMA9 microglia
cells were treated for 7 days in 1% serum solution with the alpha secretase
inhibitor GI254023X, the beta secretase inhibitor Verubecestat, or the gamma
secretase inhibitor DAPT (Fig 20A). No significant difference was found in the
IDE protein content of SIMA9 cells treated with inhibitors compared to untreated
or vehicle controls (n=3/treatment, p=0.45) by one-way ANOVA.
Next, to further examine if an APP metabolite may be capable of changing
IDE levels, we tested if the application of recombinant sAPP fragments to APP-/astrocyte primary cultures would reduce the protein levels of IDE. Cells were
treated for 3 days with 20 nM of bacterial derived recombinant sAPPα, sAPPβ or
mutant sAPPa, or with 200 nM eukaryotic derived sAPPα695 or sAPPα751 (Fig
20B). These sAPP fragments did not alter IDE levels in cultures, further
suggesting the full length APP protein or another APP fragment may be
upstream of changes in IDE levels observed in APP-/- tissues.
Finally, we tested if overexpression of the APP695 isoform or the APP751
isoform in APP-/- astrocytes is sufficient to reduce levels of IDE (Fig 20C).
Primary astrocyte cultures were transfected using lipofectamine with plamsids
coding for APP695, APP751, Green fluorescent protein (GFP), or mock
transfected as a control. Cellular protein was collected after 5 days and IDE was
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Figure 20.

APP fragments and secretase inhibitors do not alter IDE.
Overexpression of APP does not alter IDE levels in APP-/- cells.
(A) SIMA9 microglia (n=3/condition) were treated with secretase
inhibitors, DMSO vehicle, or left untreated for one week and IDE
protein content was measured. Significance p<0.05* was
determined by one-way ANOVA.
(B) APP-/- primary astrocyte cultures (n=4/condition) were treated
with bacterial recombinant sAPPα, sAPPβ, mutant n-terminal
truncated sAPPα or euaryotic derived sAPPα695 and 751. IDE
protein was measured and significance p<0.05* was determined by
one-way ANOVA.
(C) APP-/- astrocyte primary cultures (n=6/condition) were
transfected with APP695, APP751 or GFP plasmids or mock
transfected. IDE protein was measured and significance p<0.05*
was determined by one-way ANOVA.
Data is graphed as ± SEM.
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measured by western blot. Surprisingly, overexpression of APP in APP-/astrocytes did not significantly change IDE levels (p=0.56) (Fig 20C). This
suggests that overexpression of APP may not be capable of restoring the normal
functions of APP, possibly due to aberrant processing of the transgene protein
product. Alternatively, overexpression of APP may not allow for normal proteinprotein interactions of the APP proteins, or that overexpressed APP may not be
trafficked appropriately to perform its normal functions within the cell.
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CHAPTER V
DISCUSSION
Study 1 - Amyloid Precursor Protein
in the Endocrine Pancreas
In this study we report the presence of APP in pancreatic tissue, including
the detection of APP within insulin producing pancreatic β cells. We have
confirmed the presence of pancreatic islet APP expression in both C57B6 mice
and human samples, demonstrating this pattern of APP expression is confirmed
across species. Interestingly, we observed APP is overexpressed within the
pancreatic islets of the APP/PS1 mouse model of AD. This mouse model of AD
uses the mouse prion promoter to drive human APP transgene expression. This
finding indicates that the prion promoter itself may be a useful tool for driving
robust gene expression of target genes specifically within the endocrine
compartment of the pancreas. It has recently been reported that a 3xTg-AD
model of Alzheimer’s disease, which uses Thy 1.2 promoter, also overexpresses
human APP within pancreatic islets (Vandal et al., 2015). Because of the
similarity in gene expression and phenotype between pancreatic islets and
neurons, it is likely that numerous genetic elements which drive high expression
of genes in the central nervous system will also result in robust gene expression
in pancreatic islets (Atouf, Czernichow, & Scharfmann, 1997; Martens et al.,
2011; Moller et al., 1992).
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Despite the robust overexpression of human mutant APP within the
pancreatic islets of the APP/PS1 mouse, we were unable to detect the presence
of monomeric human Aβ, Aβ oligomers, or fibrils within APP/PS1 pancreatic
tissue or islet cultures by ELISA or immunohistochemistry. This is in agreement
with previous reports suggesting β-secretase activity is not present in pancreatic
tissue extractions despite the presence of BACE1 RNA (Ehehalt et al., 2002;
Mowrer & Wolfe, 2008; Sinha et al., 1999). In 2002, Ehehalt et al. described a
shorter isoform of BACE1 RNA termed BACE1C in the pancreas along with the
more well-known BACE1A isoform. BACE1C lacked detectable β-secretase
activity in their assays, suggesting that pancreatic tissue may not produce Aβ, in
part, because of the presence of this enzymatically inactive splice variant.
However, BACE1A is still the dominant isoform of BACE1 found in the pancreas
so alternative splicing cannot be the sole reason for this phenomenon. In 2008,
Mowrer and Wolfe described similar alternative splicing of BACE1 in the
pancreas relative to the brain, but also noted that this alone was not sufficient to
explain the lack of BACE1 activity in pancreatic tissue. These authors postulated
that pancreatic BACE1 is inactive due to post-translational processing
mechanisms. Indeed, it has been shown that BACE1 in the pancreas and other
tissues undergoes differential proteolytic processing compared to the brain
resulting in lower or undetectable levels of the BACE1 holoprotein (Huse et al.,
2003). Instead of β-secretase mediated APP processing, our data suggests that
APP in pancreatic islets is processed by α-secretase activity to release sAPPα.
This is clearly in contrast to the CNS where both forms of APP processing occur.
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We were also unable to detect plaque deposition in human pancreas sections
using the anti-Aβ antibody, 4G8. It is possible that pancreatic islets could be
affected by circulating concentrations of Aβ rather than locally produced Aβ.
To study the significance of APP in pancreatic islet function, we examined
two month old WT, APP-/-, and APP/PS1 animals for differences in glucose
tolerance by oral gavage. This time point was important for assessing the role of
islet APP in glucose tolerance because it is well before Aβ deposits are known to
form in the CNS of the APP/PS1 mouse. Aβ oligomers or over-overexpression of
the Aβ producing enzyme BACE1 in the brain have recently been demonstrated
as sufficient to induce peripheral metabolic dysregulation (J. R. Clarke et al.,
2015; Plucinska et al., 2016). We detected no significant differences in glucose
tolerance across strain, indicating ablation or overexpression of mutant APP
does not severely compromise glucose homeostasis mechanisms or severely
impair islet function at two months of age. Multiple organ systems such as liver
and kidney gluconeogenesis and muscle glucose uptake are involved in glucose
homeostasis, thus the effect of overexpression or ablation of pancreatic islet APP
on blood glucose levels during glucose tolerance testing may be masked by
glucose-regulating compensatory mechanisms in other organs. In addition to
glucose tolerance testing, we also measured the pancreatic insulin and glucagon
content by ELISA. Our results indicate that while total insulin content was
unchanged, total pancreatic glucagon levels and glucagon immunostaining were
significantly attenuated in animals expressing the APP/PS1 transgenes,
suggesting that overexpression of mutant APP or presenilin in pancreatic islets
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may alter the development of α cells or affect their secretory functions. BACE2
levels were also diminished in the APP/PS1 animals, further suggesting that the
APP/PS1 mice may have fewer pancreatic α cells. Future work requiring,
perhaps stereologic assessment, may provide a clearer indication of changes in
total α cell numbers in the APP/PS1 compared to WT mice. One possible
mechanism for a change in α cell number could be through alterations in Notch
biology. Presenilin is part of the γ–secretase complex which cleaves the Notch
protein to liberate the biologically active NICD fragment. NICD then enters the
nucleus where it affects transcription(Chan & Jan, 1999). Notch signaling is
thought to play a critical role in the normal development of the endocrine
pancreas suggesting that mutant presenilin expression in the pancreas may
indeed influence this biology (Hald et al., 2003; Jensen et al., 2000; Murtaugh,
Stanger, Kwan, & Melton, 2003).
Our examinations of pancreatic protein content in two month old animals
revealed changes in the levels of IDE, GLUT4 and BACE2. Animals lacking the
APP gene showed increased levels of IDE and GLUT4, while APP-/- and
APP/PS1 animals showed reduced BACE2 levels compared to wild type in
western blot. IDE has been identified as an enzyme capable of degrading Aβ and
amylin in addition to insulin. These functions may be important in the pancreas,
as inhibition of IDE has been shown to enhance toxicity of islet amylin (R. G.
Bennett, Hamel, & Duckworth, 2003). GLUT4 is considered the insulin
responsive glucose transporter and is well known for its role in muscle and fat
tissue. Recent studies have presented evidence that both sAPP and Aβ may
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influence the cellular localization of GLUT4 (Hamilton et al., 2014; Oliveira et al.,
2015). BACE2 has been previously implicated as both an APP cleaving enzyme
and regulator of β cell function through the cleavage of the transmembrane
protein TMEM27 (Esterhazy et al., 2011). It has been proposed that full length
TMEM27 supports beta cell growth and insulin secretion, thus blocking its
cleavage by inhibiting BACE2 activity may represent a therapeutic strategy to
control blood glucose in diabetic patients (Southan, 2013).
We also examined protein content of primary islet cultures from 12 month
old WT, APP-/-, and APP/PS1 animals. Similar to whole-pancreas extracts, IDE
was present at higher levels in APP-/- compared to WT controls. This indicates
that APP may play a role in negatively regulating the expression of IDE, or that
differences in the APP-/- animals lead to upregulated IDE expression. We could
not detect GLUT4 in our islet lysates, however GLUT4 is not considered a major
glucose transporter in the pancreatic endocrine cells and differences observed in
whole pancreas were likely from other cell types. BACE2 levels were not
significantly different in islets from transgenic animals compared to controls,
which is in contrast to both our immunohistochemistry and whole pancreas
western blot results. This could be in part due to the process of pancreatic islet
isolation in which the pancreas is digested with proteases to liberate the islets
from exocrine tissue. It is likely that this isolation process would affect the cells at
the islet periphery expressing BACE2. Alternatively some BACE2 in whole
pancreatic extracts may be due to the contribution of other cell types.
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Although higher glucose culture concentrations are reported to improve
islet culture and reduce apoptosis, we chose to avoid high glucose levels that
may influence APP expression or processing. Several lines of evidence suggest
that culturing cells in high glucose concentrations can alter APP processing and
affect APP protein levels (H. J. Lee et al., 2016; Yang, Wu, Zhang, & Song,
2013). Additionally, a recent study utilizing glucose clamps to sustain
hyperglycemia demonstrates that increasing glucose concentrations in vivo alters
APP processing to influence Aβ levels in the CSF (Macauley et al., 2015). We
considered the implications of these studies and thus 5mM glucose was selected
for our paradigm. We avoided larger islets with necrotic centers in an attempt to
minimize artifacts induced by cell death from lower glucose concentrations.
However, since islet glucose concentration exposure in vivo may be well above
5mM, there was a concern that our primary islet sAPPα stimulation paradigm
was superimposed upon a glucose deficient condition. To verify that sAPPα
stimulated insulin secretion at higher glucose concentrations, we employed the
MIN6 cell line to demonstrate that insulin secretion was still potentiated at
16.7 mM glucose concentration. Future studies will require further optimization of
islet culture conditions including higher glucose concentrations. In addition, it is
important to remember that although the wild type mice are littermate controls of
the APP/PS1 mice in our study, the APP-/- mice were derived from a
homozygous colony and comparison to the other two lines is potentially limited
by this. Nevertheless, these data suggest changes in pancreatic APP content or
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processing may result in alterations in the levels of proteins important to
pancreatic physiology and influence the pathology of pancreatic diseases.
Interestingly, our immunohistochemistry data indicated that primary
antibodies directed against BACE2 showed increased binding in pancreatic α
cells compared to β cells in both mouse and human tissue. This is particularly
interesting as BACE inhibitors are actively being explored as a therapeutic
strategy in AD (Kennedy et al., 2016). Our detection of BACE2 in α cells is in
contrast to reports indicating the highest pancreatic BACE2 expression is found
within pancreatic β cells (Esterhazy et al., 2011; Finzi et al., 2008). A likely
reason for this discrepancy is the binding site of the antibody used to detect
pancreatic BACE2. BACE1 and BACE2 share a high degree of sequence
similarity, and several alternatively spliced transcripts of BACE1 are known to be
present in the pancreas (Ehehalt et al., 2002; Mowrer & Wolfe, 2008). In
agreement with our findings, a recent study by Segerstolpe et al. also observed
higher expression of BACE2 in α cells relative to β cells through single cell
transcription profiling (Segerstolpe et al., 2016). In this study we utilized a
polyclonal antibody raised against the BACE2 pro-domain sequence not present
in the BACE1 sequence. Pro-domain cleavage is thought to be an essential step
in the activation of the BACE2 proenzyme, thus our immunohistochemistry
results could indicate differences in BACE2 activation in α and β cells (Hussain,
Christie, Schneider, Moore, & Dingwall, 2001; Hussain et al., 2000).
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Our assessments of isolated pancreatic islets demonstrate both
endogenous murine APP and transgenic human APP are released as sAPP into
culture media from WT and APP/PS1 mouse islets respectively. We also
observed modest but significant differences in the insulin secretion properties of
islets overexpressing or lacking APP compared to WT controls, suggesting the
presence of APP may influence the basic functional properties of β cells in vitro.
However, a lack of detectable differences in APP-/- and APP/PS1 animals
compared to WT controls in glucose tolerance testing at two months of age
suggests APP is not essential for normal islet insulin secretion or glucose
homeostasis in vivo.
sAPP has been shown to exert effects on a variety of cell types. In the
central nervous system, sAPP is thought to promote neurite outgrowth and
influence the differentiation of neural stem cells (Baratchi, Evans, Tate, Abraham,
& Connor, 2012; Freude, Penjwini, Davis, LaFerla, & Blurton-Jones, 2011; Jin et
al., 1994; Porayette et al., 2009). sAPP has also been implicated as having
growth enhancing effect in pancreatic cancer, in addition to altering the
proliferation rate of other cell types (Demars, Bartholomew, Strakova, & Lazarov,
2011; Hansel et al., 2003; Woods & Padmanabhan, 2013). Our data indicate that
recombinant sAPPα modestly potentiates insulin secretion in pancreatic islets
from both mice and humans in vitro. This suggests that sAPP may exert effects
on β cell function, potentially by acting on cell surface receptors in an autocrine
fashion. The mechanism through which sAPP exerts its biological effects is
uncertain and may be due to interactions with several proteins. Several studies
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have identified putative cell surface receptors for sAPP. These include the P75
neurotrophic receptor, LRP1, as well as APP itself (Hasebe et al., 2013; Kounnas
et al., 1995). The putative receptors and biological effects of sAPP signaling have
recently been extensively reviewed (Habib, Sawmiller, & Tan, 2016). Stimulation
of these cell surface receptors by sAPP may influence the survival or phenotype
of islets in culture. Indeed, recombinant sAPP has been shown to induce cell
signaling cascades which may account for its effects on cultured islets (Bodles &
Barger, 2005; Deng et al., 2015; Jimenez et al., 2011). Our future work will focus
on identifying signaling cascades and downstream effects induced in pancreatic
endocrine cells by both APP and sAPP.
To our knowledge, our study is the first report showing sAPP is released
from both primary mouse and human islet cultures into culture media. We also
present new data indicating expression of the BACE2 protein in pancreatic α
cells. Findings from this study contribute to the basic understanding of amyloid
precursor protein and pancreatic islet physiology.
Study 2 - Amyloid Precursor Protein
and Insulin Degrading Enzyme
Glucose hypometabolism in the brain is a known component of advanced
Alzheimer’s disease and is also observed in animal models of AD and in Down
syndrome patients (Lao et al., 2018; Oh, Madison, Baker, Rabinovici, & Jagust,
2016; Parent et al., 2017). Type 2 diabetes is also among the risk factors for the
development of AD (Wijesekara, Goncalves da Silva, De Felice, & Fraser, 2017).
Interestingly, growing research indicates that a normal physiologic function of
APP and its associated fragments are regulators metabolic homeostasis. APP-/91

knockout mice, in addition to having lower body weight, show reduced weight
gain when placed on a high fat diet (Puig et al., 2017). In muscle tissue, sAPPα
has been shown to potentiate glucose uptake (Hamilton et al., 2014). APP’s role
in metabolism may also be conserved across species. APL-1, the C. elegans
homologue of APP, is both essential for survival and may play an important role
in insulin homeostasis and metabolism (Ewald, Cheng, et al., 2012; Ewald & Li,
2012; Ewald, Raps, & Li, 2012; Puig et al., 2017). Our data presented in this
study indicates that ablation of the APP gene in mice or prolonged knockdown of
the APP gene in cell culture results in increased levels of the insulin degrading
enzyme (IDE) and changes in insulin signaling compared to controls. Increased
IDE protein levels were found to be present in muscle, liver and in hippocampal
tissue extracts from APP-/- animals. In agreement with this finding, primary cell
cultures of neurons, astrocytes and microglia from APP-/- mice were all found to
have higher IDE content than WT control primary cultures. Furthermore, mRNA
levels of IDE were found to be significantly increased in hippocampal tissue
extracts from APP-/- animals compared to controls, suggesting that increased
IDE protein is the result of increased transcription of the IDE gene. The
phenomenon of increased IDE was most robust in brain tissue and neurons
relative to other tissues and cell types assessed in this study, which is interesting
because APP, although expressed ubiquitously, is known to be particularly
abundant in neuronal cells and generally abundant in the CNS. In further support
of this observation treatment of SIMA9 microglial cells with anti-APP siRNA for
one week was sufficient to increase protein levels of IDE. This suggests that loss
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of APP directly mediates this effect, and it is not a consequence of broad
changes in APP-/- animal development and metabolism.
To determine if increased levels of IDE protein resulted in functional
differences in enzyme activity, we measured the activity of IDE in liver, muscle
and brain tissue. In agreement with our western blot data, we observed robust
and significantly increased IDE activity in both hippocampus and liver extracts
from APP-/- animals compared to WT controls. IDE activity was surprisingly not
statistically different in skeletal muscle tissue extracts, despite increased total
IDE proteins levels. The lack of difference in muscle could be due to the nature of
the activity assay, which uses cleavage of a FRET peptide as an indicator of IDE
activity. It is possible that muscle tissue contains other enzymes capable of
cleaving the FRET substrate, or that our protocol of homogenization was not
sufficiently rigorous to liberate all of the IDE from the gastrocnemius muscle
tissue. Alternatively, we observed additional lower molecular weight bands on
western blots for IDE from muscle tissue lysates not present in other tissues,
suggesting a there may be alternative forms of IDE in muscle compared to other
tissues.
The ability of an enzyme present in tissue extracts to degrade insulin has
been known for decades, and an insulin degrading enzyme was purified and
further characterized by Duckworth et al. in 1972 (Duckworth, Heinemann, &
Kitabchi, 1972; Mirsky & Broh-Kahn, 1949). In 1988, the IDE was cloned and
definitively identified (Affholter, Fried, & Roth, 1988). While the brain was
traditionally viewed as an insulin insensitive organ, increasing literature
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demonstrates insulin and insulin signaling are involved in the normal physiology
of the brain (Fernandez et al., 2017; Garcia-Caceres et al., 2016; Kleinridders et
al., 2014). Moreover, evidence suggests that impaired insulin signaling may play
a role in the pathology of AD (Ribe & Lovestone, 2016; Talbot et al., 2012).
Intranasal insulin is currently under investigation as a therapeutic intervention for
AD (Chapman, Schioth, Grillo, & Benedict, 2017). To determine if increased IDE
in brain tissue results in lower levels of tissue insulin content we measured the
total insulin content in lysates from WT and APP-/- hippocampal extracts by
ELISA. We observed significantly reduced insulin levels in the hippocampus of
APP-/- animals, suggesting that increased IDE activity in these animals may
indeed lower tissue insulin content or increase insulin catabolism in
homogenates. This is in general agreement with previous research showing IDE/- mice have impaired tissue insulin degradation (Farris et al., 2003).
Our data indicates that increased IDE protein and activity alter brain
insulin signaling. We examined hippocampus protein extracts for markers of
insulin signaling. While we could not clearly detect phosphorylated insulin
receptor in our hippocampus homogenates, likely due to the transient nature of
insulin receptor phosphorylation, we did observe modest but significantly reduced
levels of pAKT(T308) in APP-/- hippocampal lysates compared to WT controls.
This indicated that insulin signaling may be impaired or altered in APP-/- brain
tissues. To further examine this possibility, we prepared synaptosomes from WT
and APP-/- hippocampal tissues and stimulated them acutely using 10 nM or
200 nM of insulin. At both concentrations of insulin tested, we observed
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diminished phosphorylation of the insulin receptor in APP-/- synaptosomes
compared to WT controls. This finding further indicates either loss of APP or
increased IDE may in turn impair insulin signaling in the brain and this may be
particularly robust at the level of the synapse.
To examine potential functional consequences of increased tissue levels
of IDE in APP-/- animals, we performed glucose tolerance testing in 12 month old
male and female WT and APP-/- animals. Pharmacological inhibition of the IDE
in vivo has been shown to alter insulin levels and affect glucose tolerance
(Deprez-Poulain et al., 2015). While we did not observe a significant difference in
overall glucose tolerance between WT and APP-/- animals, we were surprised to
observe that when aged APP-/- animals were fasted they became hypoglycemic.
This is in contrast to our prior analysis of glucose levels in 2 month APP-/animals, which did not reveal this phenomenon despite increased levels of
pancreatic IDE (Kulas et al., 2017). This finding is, however, is in general
agreement with work by Needham et al. which demonstrated lower plasma
glucose in both APP-/- and APLP2-/- mice (Needham et al., 2008). Other groups
have shown that aged APP-/- animals have impaired spatial learning in advanced
age (U. Muller et al., 1994; Phinney et al., 1999). It can be speculated that aging
may reveal phenotypes in present in APP-/- mice not observed at earlier ages.
Furthermore, this compromised metabolic homeostasis may reveal the potentially
deleterious consequences of increased IDE in tissues, in spite of normal overall
glucose tolerance. IDE has been implicated in the degradation of the glucose
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elevating hormone glucagon, which may account for this phenomenon in part
(Shen, Joachimiak, Rosner, & Tang, 2006).
The mechanism by which ablation of APP results in increased IDE
transcription remains to be elucidated. It has been demonstrated that the
intracellular c-terminal fragment can interact with other proteins like Fe65 and the
histone acetyltransferase Tip60 to effect transcription (Cao & Sudhof, 2001;
Kimberly et al., 2001). However, treatment of SIMA9 microglia with secretase
inhibitors for one week was not sufficient to significantly change IDE levels in
SIMA9 cells, potentially implicating full length APP or an alternative secretase as
the primary mechanistic regulator upstream of changes in IDE. Previous
research has indicated that APP may be able to affect transcription
independently of γ-secretase activity (Hass & Yankner, 2005). Furthermore, in
vitro treatment of APP-/- astrocytes with recombinant sAPPα or sAPPβ, or SIMA9
cells with α and β secretase inhibitors did not alter IDE levels, further implication
a mechanism involving the full length APP protein. In spite of this,
overexpression of human APP695 and APP751 was not sufficient to change IDE
levels in APP-/- astrocyte primary cultures. However, this may be due to
abnormal processing or trafficking of overexpressed APP. It is also possible that
overexpression results in failure of the endogenous signaling machinery present
under WT conditions. Nonetheless, long-term siRNA knockdown of APP in vitro
was sufficient to robustly change IDE levels in support of our observations in the
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APP-/- mouse. It is possible that changes in IDE occur as an indirect effect of
loss of APP instead of APP being directly involved in IDE transcription.
IDE has previously been linked to APP in that IDE is known to degrade
both the Aβ and AICD peptide fragments of APP. In this study we present new
evidence that ablation of APP is sufficient to increase IDE transcription, protein
levels and activity both in the brain and in peripheral organs. These findings
represent a new link connecting APP to metabolic homeostasis and expand on
the already substantial number of links suggesting aberrant metabolic processes
may play a critical role in Alzheimer’s Disease.
Limitations of Work Presented in this Dissertation
The research presented in this dissertation indicates a role for APP in
insulin homeostasis and animal metabolism. The limitations of the work
discussed in this study are presented as follows.
Data presented in these studies primarily report on differences observed
across various strains of mice. Each mouse strain in this study, while originally
developed on a C57BL6 background, likely has unique attributes due to both
inbreeding of animals and having different origins. It is well established that
various behavioral, metabolic and biochemical differences occur across mouse
strains (Avila, Kim, & Massett, 2017; Linder, 2006; Vaillant et al., 2014). Thus,
differences in animal background may account for at least some of the metabolic
and protein changes observed in APP-/- and APP/PS1 animal tissues. The role
of sex as a factor of APP in influencing metabolic homeostasis was not rigorously
examined in these studies, and most experiments here utilized female animals.
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However, differences in IDE and fasting blood glucose reported here in APP-/females were also observed in male mice.
sAPPα stimulation of pancreatic endocrine cells may not represent
physiologic conditions. In this dissertation recombinant sAPPα was applied at
concentrations of 10-20 nM. This concentration was chosen based on the known
effects of sAPPα in stimulating signaling and neuroprotective effects in neurons
(Jimenez et al., 2011). The true concentration of sAPP in the blood is likely
different than this concentration. It has been shown that mice which express
human sAPPα have concentrations of approximately 200 nM in plasma, while
humans have been shown to have approximately 10-20 ng sAPPα/mg plasma
protein (Bailey et al., 2012; Ray, Long, Sokol, & Lahiri, 2011). Moreover, the
effect of recombinant sAPPα on cultures pancreatic islet insulin secretion was
modest and no difference in glucose tolerance was detected across strain. This
could indicate sAPP may only play a minor role in affecting islet function in vivo,
or that its effects on islets involve biological parameters not measured in these
studies.
Regarding the role of APP in regulating IDE, all experiments in this study
utilized either mouse tissues or mouse-derived cell lines and primary cultures.
Thus, APP regulation of IDE is not demonstrated to be conserved in humans
here. The mechanism of APP regulation of IDE remains uncertain and may be
due to downstream dysfunction following APP ablation, rather than APP directly
mediating transcription of the gene. Thus, the mechanistic relationship between
APP and IDE awaits more investigation.
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Summary Conclusions and Future Directions
The work presented in this study suggests the APP protein plays a role in
insulin homeostasis independent of its role in Aβ production (Summary Fig 21).
APP and its metabolites are detectable in the pancreas, where they may
influence pancreatic physiology and pancreatic insulin release. Furthermore, loss
of APP increases IDE levels and activity, suggesting a role for APP in whole
body insulin turnover and signaling. Ablation of APP in mice leads to broad
metabolic changes including hypoglycemia which occur as a function of age and
are revealed by fasting.
Future work to expand on these studies will examine APP in the Min6 cell
line. We have begun to characterize APP in this pancreatic β cell line and
observe similar processing and release of APP into conditioned media as
observed in the primary pancreatic islet cultures presented in this dissertation.
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Figure 21.

Model of Pancreatic APP and summarized findings.
(A) Pancreatic α and β cell APP is processed through the αsecretase pathway to yield sAPPα which is detected in pancreatic
cell culture media. sAPPα exerts effects on cells, possibly by acting
on cell surface proteins in an autocrine or paracrine manner to
effect pancreatic β cell phenotype. Full length APP itself may serve
as a receptor for sAPP or drive downstream events independently
of sAPPα.
(B) APP-/- mice show elevated IDE protein and activity in numerous
tissues including the brain. These mice also display low
hippocampal insulin content and impaired insulin signaling. APP-/animals also show impaired glucose homeostasis when fasted.

100

REFERENCES
Affholter, J. A., Fried, V. A., & Roth, R. A. (1988). Human insulin-degrading
enzyme shares structural and functional homologies with E. coli protease
III. Science, 242(4884), 1415-1418.
Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An
English translation of Alzheimer's 1907 paper, "Uber eine eigenartige
Erkankung der Hirnrinde". Clin Anat, 8(6), 429-431. doi:
10.1002/ca.980080612
Apostolatos, A., Song, S., Acosta, S., Peart, M., Watson, J. E., Bickford, P., . . .
Patel, N. A. (2012). Insulin promotes neuronal survival via the alternatively
spliced protein kinase CdeltaII isoform. J Biol Chem, 287(12), 9299-9310.
doi: 10.1074/jbc.M111.313080
Arai, H., Lee, V. M., Messinger, M. L., Greenberg, B. D., Lowery, D. E., &
Trojanowski, J. Q. (1991). Expression patterns of beta-amyloid precursor
protein (beta-APP) in neural and nonneural human tissues from
Alzheimer's disease and control subjects. Ann Neurol, 30(5), 686-693. doi:
10.1002/ana.410300509
Ashcroft, F. M., & Rorsman, P. (2012). Diabetes mellitus and the beta cell: the
last ten years. Cell, 148(6), 1160-1171. doi: 10.1016/j.cell.2012.02.010
Atouf, F., Czernichow, P., & Scharfmann, R. (1997). Expression of neuronal traits
in pancreatic beta cells. Implication of neuron-restrictive silencing
factor/repressor element silencing transcription factor, a neuron-restrictive
silencer. J Biol Chem, 272(3), 1929-1934.
Avila, J. J., Kim, S. K., & Massett, M. P. (2017). Differences in Exercise Capacity
and Responses to Training in 24 Inbred Mouse Strains. Front Physiol, 8,
974. doi: 10.3389/fphys.2017.00974
Bailey, A. R., Giunta, B. N., Obregon, D., Nikolic, W. V., Tian, J., Sanberg, C. D.,
. . . Tan, J. (2008). Peripheral biomarkers in Autism: secreted amyloid
precursor protein-alpha as a probable key player in early diagnosis. Int J
Clin Exp Med, 1(4), 338-344.

101

Bailey, A. R., Hou, H., Obregon, D. F., Tian, J., Zhu, Y., Zou, Q., . . . Tan, J.
(2012). Aberrant T-lymphocyte development and function in mice
overexpressing human soluble amyloid precursor protein-alpha:
implications for autism. FASEB J, 26(3), 1040-1051. doi: 10.1096/fj.11195438
Banati, R. B., Gehrmann, J., Czech, C., Monning, U., Jones, L. L., Konig, G., . . .
Kreutzberg, G. W. (1993). Early and rapid de novo synthesis of Alzheimer
beta A4-amyloid precursor protein (APP) in activated microglia. Glia, 9(3),
199-210. doi: 10.1002/glia.440090305
Baratchi, S., Evans, J., Tate, W. P., Abraham, W. C., & Connor, B. (2012).
Secreted amyloid precursor proteins promote proliferation and glial
differentiation of adult hippocampal neural progenitor cells. Hippocampus,
22(7), 1517-1527. doi: 10.1002/hipo.20988
Baura, G. D., Foster, D. M., Porte, D., Jr., Kahn, S. E., Bergman, R. N., Cobelli,
C., & Schwartz, M. W. (1993). Saturable transport of insulin from plasma
into the central nervous system of dogs in vivo. A mechanism for
regulated insulin delivery to the brain. J Clin Invest, 92(4), 1824-1830. doi:
10.1172/jci116773
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015). Aberrant
insulin signaling in Alzheimer's disease: current knowledge. Front
Neurosci, 9, 204. doi: 10.3389/fnins.2015.00204
Beer, J., Masters, C. L., & Beyreuther, K. (1995). Cells from peripheral tissues
that exhibit high APP expression are characterized by their high
membrane fusion activity. Neurodegeneration, 4(1), 51-59.
Bennett, B. D., Babu-Khan, S., Loeloff, R., Louis, J. C., Curran, E., Citron, M., &
Vassar, R. (2000). Expression analysis of BACE2 in brain and peripheral
tissues. J Biol Chem, 275(27), 20647-20651. doi:
10.1074/jbc.M002688200
Bennett, R. G., Hamel, F. G., & Duckworth, W. C. (2003). An insulin-degrading
enzyme inhibitor decreases amylin degradation, increases amylin-induced
cytotoxicity, and increases amyloid formation in insulinoma cell cultures.
Diabetes, 52(9), 2315-2320.
Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., . . . Tanzi, R.
E. (2000). Evidence for genetic linkage of Alzheimer's disease to
chromosome 10q. Science, 290(5500), 2302-2303. doi:
10.1126/science.290.5500.2302

102

Best, J. D., Taborsky, G. J., Jr., Halter, J. B., & Porte, D., Jr. (1981). Glucose
disposal is not proportional to plasma glucose level in man. Diabetes,
30(10), 847-850.
Beydoun, M. A., Beydoun, H. A., & Wang, Y. (2008). Obesity and central obesity
as risk factors for incident dementia and its subtypes: a systematic review
and meta-analysis. Obes Rev, 9(3), 204-218. doi: 10.1111/j.1467789X.2008.00473.x
Biessels, G. J., Deary, I. J., & Ryan, C. M. (2008). Cognition and diabetes: a
lifespan perspective. Lancet Neurol, 7(2), 184-190. doi: 10.1016/s14744422(08)70021-8
Biessels, G. J., Kamal, A., Urban, I. J., Spruijt, B. M., Erkelens, D. W., & Gispen,
W. H. (1998). Water maze learning and hippocampal synaptic plasticity in
streptozotocin-diabetic rats: effects of insulin treatment. Brain Res, 800(1),
125-135.
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006).
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol,
5(1), 64-74. doi: 10.1016/s1474-4422(05)70284-2
Blanquet, V., Goldgaber, D., Turleau, C., Creau-Goldberg, N., Delabar, J., Sinet,
P. M., . . . de Grouchy, J. (1987). The beta amyloid protein (AD-AP) cDNA
hybridizes in normal and Alzheimer individuals near the interface of 21q21
and q22.1. Ann Genet, 30(2), 68-69.
Bodles, A. M., & Barger, S. W. (2005). Secreted beta-amyloid precursor protein
activates microglia via JNK and p38-MAPK. Neurobiol Aging, 26(1), 9-16.
doi: 10.1016/j.neurobiolaging.2004.02.022
Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J. C.,
Decker, H., . . . De Felice, F. G. (2012). An anti-diabetes agent protects
the mouse brain from defective insulin signaling caused by Alzheimer's
disease- associated Abeta oligomers. J Clin Invest, 122(4), 1339-1353.
doi: 10.1172/jci57256
Bondy, C. A., Zhou, J., Chin, E., Reinhardt, R. R., Ding, L., & Roth, R. A. (1994).
Cellular distribution of insulin-degrading enzyme gene expression.
Comparison with insulin and insulin-like growth factor receptors. J Clin
Invest, 93(3), 966-973. doi: 10.1172/jci117103
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002).
Sniffing neuropeptides: a transnasal approach to the human brain. Nat
Neurosci, 5(6), 514-516. doi: 10.1038/nn849

103

Braak, H., & Braak, E. (1997a). Diagnostic criteria for neuropathologic
assessment of Alzheimer's disease. Neurobiol Aging, 18(4 Suppl), S8588.
Braak, H., & Braak, E. (1997b). Staging of Alzheimer-related cortical destruction.
Int Psychogeriatr, 9 Suppl 1, 257-261; discussion 269-272.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem, 72, 248-254.
Bruning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., .
. . Kahn, C. R. (2000). Role of brain insulin receptor in control of body
weight and reproduction. Science, 289(5487), 2122-2125.
Burns, C. M., Rutherford, M. A., Boardman, J. P., & Cowan, F. M. (2008).
Patterns of cerebral injury and neurodevelopmental outcomes after
symptomatic neonatal hypoglycemia. Pediatrics, 122(1), 65-74. doi:
10.1542/peds.2007-2822
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P. O., &
Caicedo, A. (2006). The unique cytoarchitecture of human pancreatic
islets has implications for islet cell function. Proc Natl Acad Sci U S A,
103(7), 2334-2339. doi: 10.1073/pnas.0510790103
Cao, X., & Sudhof, T. C. (2001). A transcriptionally [correction of transcriptively]
active complex of APP with Fe65 and histone acetyltransferase Tip60.
Science, 293(5527), 115-120. doi: 10.1126/science.1058783
Chan, Y. M., & Jan, Y. N. (1999). Presenilins, processing of beta-amyloid
precursor protein, and notch signaling. Neuron, 23(2), 201-204.
Chapman, C. D., Schioth, H. B., Grillo, C. A., & Benedict, C. (2017). Intranasal
insulin in Alzheimer's disease: Food for thought. Neuropharmacology. doi:
10.1016/j.neuropharm.2017.11.037
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., . .
. Selkoe, D. J. (1992). Mutation of the beta-amyloid precursor protein in
familial Alzheimer's disease increases beta-protein production. Nature,
360(6405), 672-674. doi: 10.1038/360672a0
Clarke, D. W., Mudd, L., Boyd, F. T., Jr., Fields, M., & Raizada, M. K. (1986).
Insulin is released from rat brain neuronal cells in culture. J Neurochem,
47(3), 831-836.

104

Clarke, J. R., Lyra, E. S. N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H.,
Beckman, D., . . . De Felice, F. G. (2015). Alzheimer-associated Abeta
oligomers impact the central nervous system to induce peripheral
metabolic deregulation. EMBO Mol Med, 7(2), 190-210. doi:
10.15252/emmm.201404183
Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan,
A., . . . Craft, S. (2015). Long-acting intranasal insulin detemir improves
cognition for adults with mild cognitive impairment or early-stage
Alzheimer's disease dementia. J Alzheimers Dis, 44(3), 897-906. doi:
10.3233/jad-141791
Cornblath, M., & Reisner, S. H. (1965). Blood glucose in the neonate and its
clinical significance. N Engl J Med, 273(7), 378-381.
Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A.,
. . . Gerton, B. (2012). Intranasal insulin therapy for Alzheimer disease and
amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol, 69(1),
29-38. doi: 10.1001/archneurol.2011.233
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H.,
. . . Friedman, S. (2017). Effects of Regular and Long-Acting Insulin on
Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. J
Alzheimers Dis, 57(4), 1325-1334. doi: 10.3233/jad-161256
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., . . .
Larson, E. B. (2013). Glucose levels and risk of dementia. N Engl J Med,
369(6), 540-548. doi: 10.1056/NEJMoa1215740
De Felice, F. G., & Ferreira, S. T. (2014). Inflammation, defective insulin
signaling, and mitochondrial dysfunction as common molecular
denominators connecting type 2 diabetes to Alzheimer disease. Diabetes,
63(7), 2262-2272. doi: 10.2337/db13-1954
de la Monte, S. M. (2014). Type 3 diabetes is sporadic Alzheimers disease: minireview. Eur Neuropsychopharmacol, 24(12), 1954-1960. doi:
10.1016/j.euroneuro.2014.06.008
de la Monte, S. M., Tong, M., Schiano, I., & Didsbury, J. (2017). Improved Brain
Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an
Experimental Model of Sporadic Alzheimer's Disease. J Alzheimers Dis,
55(2), 849-864. doi: 10.3233/jad-160656

105

Demars, M. P., Bartholomew, A., Strakova, Z., & Lazarov, O. (2011). Soluble
amyloid precursor protein: a novel proliferation factor of adult progenitor
cells of ectodermal and mesodermal origin. Stem Cell Res Ther, 2(4), 36.
doi: 10.1186/scrt77
Deng, J., Habib, A., Obregon, D. F., Barger, S. W., Giunta, B., Wang, Y. J., . . .
Tan, J. (2015). Soluble amyloid precursor protein alpha inhibits tau
phosphorylation through modulation of GSK3beta signaling pathway. J
Neurochem, 135(3), 630-637. doi: 10.1111/jnc.13351
Deprez-Poulain, R., Hennuyer, N., Bosc, D., Liang, W. G., Enee, E., Marechal,
X., . . . Deprez, B. (2015). Catalytic site inhibition of insulin-degrading
enzyme by a small molecule induces glucose intolerance in mice. Nat
Commun, 6, 8250. doi: 10.1038/ncomms9250
Devaskar, S. U., Giddings, S. J., Rajakumar, P. A., Carnaghi, L. R., Menon, R.
K., & Zahm, D. S. (1994). Insulin gene expression and insulin synthesis in
mammalian neuronal cells. J Biol Chem, 269(11), 8445-8454.
Devaskar, S. U., Singh, B. S., Carnaghi, L. R., Rajakumar, P. A., & Giddings, S.
J. (1993). Insulin II gene expression in rat central nervous system. Regul
Pept, 48(1-2), 55-63.
Dhawan, G., Floden, A. M., & Combs, C. K. (2012). Amyloid-beta oligomers
stimulate microglia through a tyrosine kinase dependent mechanism.
Neurobiol Aging, 33(10), 2247-2261. doi:
10.1016/j.neurobiolaging.2011.10.027
Dodart, J. C., Mathis, C., Bales, K. R., Paul, S. M., & Ungerer, A. (1999). Early
regional cerebral glucose hypometabolism in transgenic mice
overexpressing the V717F beta-amyloid precursor protein. Neurosci Lett,
277(1), 49-52.
Duckworth, W. C. (1988). Insulin degradation: mechanisms, products, and
significance. Endocr Rev, 9(3), 319-345. doi: 10.1210/edrv-9-3-319
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998). Insulin degradation:
progress and potential. Endocr Rev, 19(5), 608-624. doi:
10.1210/edrv.19.5.0349
Duckworth, W. C., Heinemann, M. A., & Kitabchi, A. E. (1972). Purification of
insulin-specific protease by affinity chromatography. Proc Natl Acad Sci U
S A, 69(12), 3698-3702.

106

Eggert, S., Paliga, K., Soba, P., Evin, G., Masters, C. L., Weidemann, A., &
Beyreuther, K. (2004). The proteolytic processing of the amyloid precursor
protein gene family members APLP-1 and APLP-2 involves alpha-, beta-,
gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by
n-glycosylation. J Biol Chem, 279(18), 18146-18156. doi:
10.1074/jbc.M311601200
Ehehalt, R., Michel, B., De Pietri Tonelli, D., Zacchetti, D., Simons, K., & Keller,
P. (2002). Splice variants of the beta-site APP-cleaving enzyme BACE1 in
human brain and pancreas. Biochem Biophys Res Commun, 293(1), 3037. doi: 10.1016/s0006-291x(02)00169-9
Espinosa, R., 3rd, Lemons, R. S., Perlman, R. K., Kuo, W. L., Rosner, M. R., &
Le Beau, M. M. (1991). Localization of the gene encoding insulindegrading enzyme to human chromosome 10, bands q23----q25.
Cytogenet Cell Genet, 57(4), 184-186.
Esterhazy, D., Stutzer, I., Wang, H., Rechsteiner, M. P., Beauchamp, J., Dobeli,
H., . . . Stoffel, M. (2011). Bace2 is a beta cell-enriched protease that
regulates pancreatic beta cell function and mass. Cell Metab, 14(3), 365377. doi: 10.1016/j.cmet.2011.06.018
Ewald, C. Y., Cheng, R., Tolen, L., Shah, V., Gillani, A., Nasrin, A., & Li, C.
(2012). Pan-neuronal expression of APL-1, an APP-related protein,
disrupts olfactory, gustatory, and touch plasticity in Caenorhabditis
elegans. J Neurosci, 32(30), 10156-10169. doi: 10.1523/jneurosci.049512.2012
Ewald, C. Y., & Li, C. (2012). The secreted Alzheimer-related amyloid precursor
protein fragment has an essential role in C. elegans. Prion, 6(5), 433-436.
doi: 10.4161/pri.22310
Ewald, C. Y., Raps, D. A., & Li, C. (2012). APL-1, the Alzheimer's Amyloid
precursor protein in Caenorhabditis elegans, modulates multiple metabolic
pathways throughout development. Genetics, 191(2), 493-507. doi:
10.1534/genetics.112.138768
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P.,
. . . Guenette, S. (2003). Insulin-degrading enzyme regulates the levels of
insulin, amyloid beta-protein, and the beta-amyloid precursor protein
intracellular domain in vivo. Proc Natl Acad Sci U S A, 100(7), 4162-4167.
doi: 10.1073/pnas.0230450100

107

Fernandez, A. M., Hernandez-Garzon, E., Perez-Domper, P., Perez-Alvarez, A.,
Mederos, S., Matsui, T., . . . Torres Aleman, I. (2017). Insulin Regulates
Astrocytic Glucose Handling Through Cooperation With IGF-I. Diabetes,
66(1), 64-74. doi: 10.2337/db16-0861
Figueroa, D. J., Shi, X. P., Gardell, S. J., & Austin, C. P. (2001). Abetapp
secretases are co-expressed with Abetapp in the pancreatic islets. J
Alzheimers Dis, 3(4), 393-396.
Finzi, G., Franzi, F., Placidi, C., Acquati, F., Palumbo, E., Russo, A., . . . La
Rosa, S. (2008). BACE2 is stored in secretory granules of mouse and rat
pancreatic beta cells. Ultrastruct Pathol, 32(6), 246-251. doi:
10.1080/01913120802486217
Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S. W., Roederer, J. P., . . .
Muller, U. C. (2016). Viral gene transfer of APPsalpha rescues synaptic
failure in an Alzheimer's disease mouse model. Acta Neuropathol, 131(2),
247-266. doi: 10.1007/s00401-015-1498-9
Franklin, W., & Taglialatela, G. (2016). A method to determine insulin
responsiveness in synaptosomes isolated from frozen brain tissue. J
Neurosci Methods, 261, 128-134. doi: 10.1016/j.jneumeth.2016.01.006
Freude, K. K., Penjwini, M., Davis, J. L., LaFerla, F. M., & Blurton-Jones, M.
(2011). Soluble amyloid precursor protein induces rapid neural
differentiation of human embryonic stem cells. J Biol Chem, 286(27),
24264-24274. doi: 10.1074/jbc.M111.227421
Gakhar-Koppole, N., Hundeshagen, P., Mandl, C., Weyer, S. W., Allinquant, B.,
Muller, U., & Ciccolini, F. (2008). Activity requires soluble amyloid
precursor protein alpha to promote neurite outgrowth in neural stem cellderived neurons via activation of the MAPK pathway. Eur J Neurosci,
28(5), 871-882. doi: 10.1111/j.1460-9568.2008.06398.x
Garcia-Caceres, C., Quarta, C., Varela, L., Gao, Y., Gruber, T., Legutko, B., . . .
Tschop, M. H. (2016). Astrocytic Insulin Signaling Couples Brain Glucose
Uptake with Nutrient Availability. Cell, 166(4), 867-880. doi:
10.1016/j.cell.2016.07.028
Glenner, G. G., & Wong, C. W. (1984). Alzheimer's disease: initial report of the
purification and characterization of a novel cerebrovascular amyloid
protein. Biochem Biophys Res Commun, 120(3), 885-890.

108

Golde, T. E., Estus, S., Usiak, M., Younkin, L. H., & Younkin, S. G. (1990).
Expression of beta amyloid protein precursor mRNAs: recognition of a
novel alternatively spliced form and quantitation in Alzheimer's disease
using PCR. Neuron, 4(2), 253-267.
Goldgaber, D., Lerman, M. I., McBride, W. O., Saffiotti, U., & Gajdusek, D. C.
(1987). Isolation, characterization, and chromosomal localization of human
brain cDNA clones coding for the precursor of the amyloid of brain in
Alzheimer's disease, Down's syndrome and aging. J Neural Transm
Suppl, 24, 23-28.
Goodner, C. J., Hom, F. G., & Berrie, M. A. (1980). Investigation of the effect of
insulin upon regional brain glucose metabolism in the rat in vivo.
Endocrinology, 107(6), 1827-1832. doi: 10.1210/endo-107-6-1827
Gordon, M. N., Holcomb, L. A., Jantzen, P. T., DiCarlo, G., Wilcock, D., Boyett,
K. W., . . . Morgan, D. (2002). Time course of the development of
Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp
Neurol, 173(2), 183-195. doi: 10.1006/exnr.2001.7754
Habib, A., Sawmiller, D., & Tan, J. (2016). Restoring Soluble Amyloid Precursor
Protein alpha Functions as a Potential Treatment for Alzheimer's Disease.
J Neurosci Res. doi: 10.1002/jnr.23823
Habib, A., Sawmiller, D., & Tan, J. (2017). Restoring Soluble Amyloid Precursor
Protein alpha Functions as a Potential Treatment for Alzheimer's Disease.
J Neurosci Res, 95(4), 973-991. doi: 10.1002/jnr.23823
Hald, J., Hjorth, J. P., German, M. S., Madsen, O. D., Serup, P., & Jensen, J.
(2003). Activated Notch1 prevents differentiation of pancreatic acinar cells
and attenuate endocrine development. Dev Biol, 260(2), 426-437.
Hamilton, D. L., Findlay, J. A., Montagut, G., Meakin, P. J., Bestow, D., Jalicy, S.
M., & Ashford, M. L. (2014). Altered amyloid precursor protein processing
regulates glucose uptake and oxidation in cultured rodent myotubes.
Diabetologia, 57(8), 1684-1692. doi: 10.1007/s00125-014-3269-x
Hansel, D. E., Rahman, A., Wehner, S., Herzog, V., Yeo, C. J., & Maitra, A.
(2003). Increased expression and processing of the Alzheimer amyloid
precursor protein in pancreatic cancer may influence cellular proliferation.
Cancer Res, 63(21), 7032-7037.

109

Harris, R. A., Tindale, L., Lone, A., Singh, O., Macauley, S. L., Stanley, M., . . .
Cumming, R. C. (2016). Aerobic Glycolysis in the Frontal Cortex
Correlates with Memory Performance in Wild-Type Mice But Not the
APP/PS1 Mouse Model of Cerebral Amyloidosis. J Neurosci, 36(6), 18711878. doi: 10.1523/jneurosci.3131-15.2016
Hasebe, N., Fujita, Y., Ueno, M., Yoshimura, K., Fujino, Y., & Yamashita, T.
(2013). Soluble beta-amyloid Precursor Protein Alpha binds to p75
neurotrophin receptor to promote neurite outgrowth. PLoS One, 8(12),
e82321. doi: 10.1371/journal.pone.0082321
Hass, M. R., & Yankner, B. A. (2005). A {gamma}-secretase-independent
mechanism of signal transduction by the amyloid precursor protein. J Biol
Chem, 280(44), 36895-36904. doi: 10.1074/jbc.M502861200
Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A., Rulicke, T., . . . Muller,
U. (2000). Mice with combined gene knock-outs reveal essential and
partially redundant functions of amyloid precursor protein family members.
J Neurosci, 20(21), 7951-7963.
Heras-Sandoval, D., Ferrera, P., & Arias, C. (2012). Amyloid-beta protein
modulates insulin signaling in presynaptic terminals. Neurochem Res,
37(9), 1879-1885. doi: 10.1007/s11064-012-0800-7
Hernandez-Garzon, E., Fernandez, A. M., Perez-Alvarez, A., Genis, L.,
Bascunana, P., Fernandez de la Rosa, R., . . . Torres Aleman, I. (2016).
The insulin-like growth factor I receptor regulates glucose transport by
astrocytes. Glia, 64(11), 1962-1971. doi: 10.1002/glia.23035
Hertz, M. M., Paulson, O. B., Barry, D. I., Christiansen, J. S., & Svendsen, P. A.
(1981). Insulin increases glucose transfer across the blood-brain barrier in
man. J Clin Invest, 67(3), 597-604. doi: 10.1172/jci110073
Herzog, V., Kirfel, G., Siemes, C., & Schmitz, A. (2004). Biological roles of APP
in the epidermis. Eur J Cell Biol, 83(11-12), 613-624. doi: 10.1078/01719335-00401
Hick, M., Herrmann, U., Weyer, S. W., Mallm, J. P., Tschape, J. A., Borgers, M., .
. . Muller, U. C. (2015). Acute function of secreted amyloid precursor
protein fragment APPsalpha in synaptic plasticity. Acta Neuropathol,
129(1), 21-37. doi: 10.1007/s00401-014-1368-x
Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., . . . Pasinetti, G. M.
(2004). Diet-induced insulin resistance promotes amyloidosis in a
transgenic mouse model of Alzheimer's disease. FASEB J, 18(7), 902904. doi: 10.1096/fj.03-0978fje

110

Hoffmann, J., Twiesselmann, C., Kummer, M. P., Romagnoli, P., & Herzog, V.
(2000). A possible role for the Alzheimer amyloid precursor protein in the
regulation of epidermal basal cell proliferation. Eur J Cell Biol, 79(12), 905914. doi: 10.1078/0171-9335-00117
Holscher, C. (2014). First clinical data of the neuroprotective effects of nasal
insulin application in patients with Alzheimer's disease. Alzheimers
Dement, 10(1 Suppl), S33-37. doi: 10.1016/j.jalz.2013.12.006
Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature,
444(7121), 860-867. doi: 10.1038/nature05485
Howell, S., Nalbantoglu, J., & Crine, P. (1995). Neutral endopeptidase can
hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid
precursor protein metabolism. Peptides, 16(4), 647-652.
Hoyer, S. (1982). The abnormally aged brain. Its blood flow and oxidative
metabolism. A review - part II. Arch Gerontol Geriatr, 1(3), 195-207.
Hoyer, S. (1986). Senile dementia and Alzheimer's disease. Brain blood flow and
metabolism. Prog Neuropsychopharmacol Biol Psychiatry, 10(3-5), 447478.
Hoyer, S. (1991). Abnormalities of glucose metabolism in Alzheimer's disease.
Ann N Y Acad Sci, 640, 53-58.
Hoyer, S., Oesterreich, K., & Wagner, O. (1988). Glucose metabolism as the site
of the primary abnormality in early-onset dementia of Alzheimer type? J
Neurol, 235(3), 143-148.
Huse, J. T., Byant, D., Yang, Y., Pijak, D. S., D'Souza, I., Lah, J. J., . . . Cook, D.
G. (2003). Endoproteolysis of beta-secretase (beta-site amyloid precursor
protein-cleaving enzyme) within its catalytic domain. A potential
mechanism for regulation. J Biol Chem, 278(19), 17141-17149. doi:
10.1074/jbc.M213303200
Hussain, I., Christie, G., Schneider, K., Moore, S., & Dingwall, C. (2001).
Prodomain processing of Asp1 (BACE2) is autocatalytic. J Biol Chem,
276(26), 23322-23328. doi: 10.1074/jbc.M101069200
Hussain, I., Powell, D. J., Howlett, D. R., Chapman, G. A., Gilmour, L., Murdock,
P. R., . . . Christie, G. (2000). ASP1 (BACE2) cleaves the amyloid
precursor protein at the beta-secretase site. Mol Cell Neurosci, 16(5), 609619. doi: 10.1006/mcne.2000.0884

111

Jacobsen, K. T., & Iverfeldt, K. (2009). Amyloid precursor protein and its
homologues: a family of proteolysis-dependent receptors. Cell Mol Life
Sci, 66(14), 2299-2318. doi: 10.1007/s00018-009-0020-8
Jensen, J., Heller, R. S., Funder-Nielsen, T., Pedersen, E. E., Lindsell, C.,
Weinmaster, G., . . . Serup, P. (2000). Independent development of
pancreatic alpha- and beta-cells from neurogenin3-expressing precursors:
a role for the notch pathway in repression of premature differentiation.
Diabetes, 49(2), 163-176.
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres,
M., Sanchez-Varo, R., . . . Vitorica, J. (2008). Inflammatory response in
the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's
disease: age-dependent switch in the microglial phenotype from
alternative to classic. J Neurosci, 28(45), 11650-11661. doi:
10.1523/jneurosci.3024-08.2008
Jimenez, S., Torres, M., Vizuete, M., Sanchez-Varo, R., Sanchez-Mejias, E.,
Trujillo-Estrada, L., . . . Vitorica, J. (2011). Age-dependent accumulation of
soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect
of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating
phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer
mouse model. J Biol Chem, 286(21), 18414-18425. doi:
10.1074/jbc.M110.209718
Jin, L. W., Ninomiya, H., Roch, J. M., Schubert, D., Masliah, E., Otero, D. A., &
Saitoh, T. (1994). Peptides containing the RERMS sequence of amyloid
beta/A4 protein precursor bind cell surface and promote neurite extension.
J Neurosci, 14(9), 5461-5470.
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., &
Calon, F. (2010). High-fat diet aggravates amyloid-beta and tau
pathologies in the 3xTg-AD mouse model. Neurobiol Aging, 31(9), 15161531. doi: 10.1016/j.neurobiolaging.2008.08.022
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L.,
Grzeschik, K. H., . . . Muller-Hill, B. (1987). The precursor of Alzheimer's
disease amyloid A4 protein resembles a cell-surface receptor. Nature,
325(6106), 733-736. doi: 10.1038/325733a0
Karamohamed, S., Demissie, S., Volcjak, J., Liu, C., Heard-Costa, N., Liu, J., . . .
Herbert, A. (2003). Polymorphisms in the insulin-degrading enzyme gene
are associated with type 2 diabetes in men from the NHLBI Framingham
Heart Study. Diabetes, 52(6), 1562-1567.

112

Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N.,
Dockendorf, M. F., . . . Forman, M. S. (2016). The BACE1 inhibitor
verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and
in Alzheimer's disease patients. Sci Transl Med, 8(363), 363ra150. doi:
10.1126/scitranslmed.aad9704
Kim, M., Hersh, L. B., Leissring, M. A., Ingelsson, M., Matsui, T., Farris, W., . . .
Tanzi, R. E. (2007). Decreased catalytic activity of the insulin-degrading
enzyme in chromosome 10-linked Alzheimer disease families. J Biol
Chem, 282(11), 7825-7832. doi: 10.1074/jbc.M609168200
Kimberly, W. T., Zheng, J. B., Guenette, S. Y., & Selkoe, D. J. (2001). The
intracellular domain of the beta-amyloid precursor protein is stabilized by
Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem,
276(43), 40288-40292. doi: 10.1074/jbc.C100447200
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014). Insulin action in
brain regulates systemic metabolism and brain function. Diabetes, 63(7),
2232-2243. doi: 10.2337/db14-0568
Kleinridders, A., Lauritzen, H. P., Ussar, S., Christensen, J. H., Mori, M. A.,
Bross, P., & Kahn, C. R. (2013). Leptin regulation of Hsp60 impacts
hypothalamic insulin signaling. J Clin Invest, 123(11), 4667-4680. doi:
10.1172/jci67615
Klevanski, M., Saar, M., Baumkotter, F., Weyer, S. W., Kins, S., & Muller, U. C.
(2014). Differential role of APP and APLPs for neuromuscular synaptic
morphology and function. Mol Cell Neurosci, 61, 201-210. doi:
10.1016/j.mcn.2014.06.004
Klockener, T., Hess, S., Belgardt, B. F., Paeger, L., Verhagen, L. A., Husch, A., .
. . Bruning, J. C. (2011). High-fat feeding promotes obesity via insulin
receptor/PI3K-dependent inhibition of SF-1 VMH neurons. Nat Neurosci,
14(7), 911-918. doi: 10.1038/nn.2847
Konig, G., Monning, U., Czech, C., Prior, R., Banati, R., Schreiter-Gasser, U., . . .
Beyreuther, K. (1992). Identification and differential expression of a novel
alternative splice isoform of the beta A4 amyloid precursor protein (APP)
mRNA in leukocytes and brain microglial cells. J Biol Chem, 267(15),
10804-10809.
Kounnas, M. Z., Moir, R. D., Rebeck, G. W., Bush, A. I., Argraves, W. S., Tanzi,
R. E., . . . Strickland, D. K. (1995). LDL receptor-related protein, a
multifunctional ApoE receptor, binds secreted beta-amyloid precursor
protein and mediates its degradation. Cell, 82(2), 331-340.

113

Kulas, J. A., Puig, K. L., & Combs, C. K. (2017). Amyloid precursor protein in
pancreatic islets. J Endocrinol, 235(1), 49-67. doi: 10.1530/joe-17-0122
Kurauti, M. A., Costa-Junior, J. M., Ferreira, S. M., Santos, G. J., Sponton, C. H.
G., Carneiro, E. M., . . . Boschero, A. C. (2017). Interleukin-6 increases
the expression and activity of insulin-degrading enzyme. Sci Rep, 7,
46750. doi: 10.1038/srep46750
Kurochkin, I. V., & Goto, S. (1994). Alzheimer's beta-amyloid peptide specifically
interacts with and is degraded by insulin degrading enzyme. FEBS Lett,
345(1), 33-37.
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018). Insulin-Degrading
Enzyme in the Fight against Alzheimer's Disease. Trends Pharmacol Sci,
39(1), 49-58. doi: 10.1016/j.tips.2017.10.008
Lao, P. J., Handen, B. L., Betthauser, T. J., Mihaila, I., Hartley, S. L., Cohen, A.
D., . . . Christian, B. T. (2018). Alzheimer-Like Pattern of Hypometabolism
Emerges with Elevated Amyloid-beta Burden in Down Syndrome. J
Alzheimers Dis, 61(2), 631-644. doi: 10.3233/jad-170720
Lee, H. J., Ryu, J. M., Jung, Y. H., Lee, S. J., Kim, J. Y., Lee, S. H., . . . Han, H.
J. (2016). High glucose upregulates BACE1-mediated Abeta production
through ROS-dependent HIF-1alpha and LXRalpha/ABCA1-regulated lipid
raft reorganization in SK-N-MC cells. Sci Rep, 6, 36746. doi:
10.1038/srep36746
Lee, H. K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009). The
insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol
Biol Cell, 20(5), 1533-1544. doi: 10.1091/mbc.E08-07-0777
Lee, K. J., Moussa, C. E., Lee, Y., Sung, Y., Howell, B. W., Turner, R. S., . . .
Hoe, H. S. (2010). Beta amyloid-independent role of amyloid precursor
protein in generation and maintenance of dendritic spines. Neuroscience,
169(1), 344-356. doi: 10.1016/j.neuroscience.2010.04.078
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell,
W. H., . . . et al. (1995). Candidate gene for the chromosome 1 familial
Alzheimer's disease locus. Science, 269(5226), 973-977.
Levy, J., & Olefsky, J. M. (1987). The effect of insulin concentration on
retroendocytosis in isolated rat adipocytes. Endocrinology, 120(2), 450456. doi: 10.1210/endo-120-2-450

114

Li, Q., & Sudhof, T. C. (2004). Cleavage of amyloid-beta precursor protein and
amyloid-beta precursor-like protein by BACE 1. J Biol Chem, 279(11),
10542-10550. doi: 10.1074/jbc.M310001200
Linder, C. C. (2006). Genetic variables that influence phenotype. ILAR J, 47(2),
132-140.
Liu, X., Teng, Z., Cui, C., Wang, R., Liu, M., & Zhang, Y. (2014). Amyloid betaderived diffusible ligands (ADDLs) induce abnormal expression of insulin
receptors in rat hippocampal neurons. J Mol Neurosci, 52(1), 124-130. doi:
10.1007/s12031-013-0216-0
Lorent, K., Overbergh, L., Moechars, D., De Strooper, B., Van Leuven, F., & Van
den Berghe, H. (1995). Expression in mouse embryos and in adult mouse
brain of three members of the amyloid precursor protein family, of the
alpha-2-macroglobulin receptor/low density lipoprotein receptor-related
protein and of its ligands apolipoprotein E, lipoprotein lipase, alpha-2macroglobulin and the 40,000 molecular weight receptor-associated
protein. Neuroscience, 65(4), 1009-1025.
Lorenzo, A., Razzaboni, B., Weir, G. C., & Yankner, B. A. (1994). Pancreatic islet
cell toxicity of amylin associated with type-2 diabetes mellitus. Nature,
368(6473), 756-760. doi: 10.1038/368756a0
Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny-Germano, L.,
Batista, A. F., . . . De Felice, F. G. (2013). TNF-alpha mediates PKRdependent memory impairment and brain IRS-1 inhibition induced by
Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab,
18(6), 831-843. doi: 10.1016/j.cmet.2013.11.002
Macauley, S. L., Stanley, M., Caesar, E. E., Yamada, S. A., Raichle, M. E.,
Perez, R., . . . Holtzman, D. M. (2015). Hyperglycemia modulates
extracellular amyloid-beta concentrations and neuronal activity in vivo. J
Clin Invest, 125(6), 2463-2467. doi: 10.1172/jci79742
Macdonald, I. R., DeBay, D. R., Reid, G. A., O'Leary, T. P., Jollymore, C. T.,
Mawko, G., . . . Darvesh, S. (2014). Early detection of cerebral glucose
uptake changes in the 5XFAD mouse. Curr Alzheimer Res, 11(5), 450460.
Macklin, L., Griffith, C. M., Cai, Y., Rose, G. M., Yan, X. X., & Patrylo, P. R.
(2017). Glucose tolerance and insulin sensitivity are impaired in APP/PS1
transgenic mice prior to amyloid plaque pathogenesis and cognitive
decline. Exp Gerontol, 88, 9-18. doi: 10.1016/j.exger.2016.12.019

115

Manocha, G. D., Floden, A. M., Rausch, K., Kulas, J. A., McGregor, B. A.,
Rojanathammanee, L., . . . Combs, C. K. (2016). APP Regulates
Microglial Phenotype in a Mouse Model of Alzheimer's Disease. J
Neurosci, 36(32), 8471-8486. doi: 10.1523/jneurosci.4654-15.2016
Mao, Y. F., Guo, Z., Zheng, T., Jiang, Y., Yan, Y., Yin, X., . . . Zhang, B. (2016).
Intranasal insulin alleviates cognitive deficits and amyloid pathology in
young adult APPswe/PS1dE9 mice. Aging Cell, 15(5), 893-902. doi:
10.1111/acel.12498
Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J., . . .
Blum, D. (2017). Tau deletion promotes brain insulin resistance. J Exp
Med, 214(8), 2257-2269. doi: 10.1084/jem.20161731
Martens, G. A., Jiang, L., Hellemans, K. H., Stange, G., Heimberg, H., Nielsen, F.
C., . . . Pipeleers, D. G. (2011). Clusters of conserved beta cell marker
genes for assessment of beta cell phenotype. PLoS One, 6(9), e24134.
doi: 10.1371/journal.pone.0024134
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., &
Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease
and Down syndrome. Proc Natl Acad Sci U S A, 82(12), 4245-4249.
Meier-Ruge, W., Bertoni-Freddari, C., & Iwangoff, P. (1994). Changes in brain
glucose metabolism as a key to the pathogenesis of Alzheimer's disease.
Gerontology, 40(5), 246-252.
Miklossy, J., Qing, H., Radenovic, A., Kis, A., Vileno, B., Laszlo, F., . . . McGeer,
P. L. (2010). Beta amyloid and hyperphosphorylated tau deposits in the
pancreas in type 2 diabetes. Neurobiol Aging, 31(9), 1503-1515. doi:
10.1016/j.neurobiolaging.2008.08.019
Mirsky, I. A., & Broh-Kahn, R. H. (1949). The inactivation of insulin by tissue
extracts; the distribution and properties of insulin inactivating extracts.
Arch Biochem, 20(1), 1-9.
Mittal, K., & Katare, D. P. (2016). Shared links between type 2 diabetes mellitus
and Alzheimer's disease: A review. Diabetes Metab Syndr, 10(2 Suppl 1),
S144-149. doi: 10.1016/j.dsx.2016.01.021
Moller, C. J., Christgau, S., Williamson, M. R., Madsen, O. D., Niu, Z. P., Bock,
E., & Baekkeskov, S. (1992). Differential expression of neural cell
adhesion molecule and cadherins in pancreatic islets, glucagonomas, and
insulinomas. Mol Endocrinol, 6(8), 1332-1342. doi:
10.1210/mend.6.8.1406710

116

Morales-Corraliza, J., Wong, H., Mazzella, M. J., Che, S., Lee, S. H., Petkova,
E., . . . Mathews, P. M. (2016). Brain-Wide Insulin Resistance, Tau
Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-beta
Alterations in a Monkey Model of Type 1 Diabetes. J Neurosci, 36(15),
4248-4258. doi: 10.1523/jneurosci.4640-14.2016
Morello, A., Lima, T. M., & Brandao, L. (2017). Language and communication
non-pharmacological interventions in patients with Alzheimer's disease: a
systematic review. Communication intervention in Alzheimer. Dement
Neuropsychol, 11(3), 227-241. doi: 10.1590/1980-57642016dn11-030004
Mosconi, L., Sorbi, S., de Leon, M. J., Li, Y., Nacmias, B., Myoung, P. S., . . .
Pupi, A. (2006). Hypometabolism exceeds atrophy in presymptomatic
early-onset familial Alzheimer's disease. J Nucl Med, 47(11), 1778-1786.
Mowrer, K. R., & Wolfe, M. S. (2008). Promotion of BACE1 mRNA alternative
splicing reduces amyloid beta-peptide production. J Biol Chem, 283(27),
18694-18701. doi: 10.1074/jbc.M801322200
Muller, U., Cristina, N., Li, Z. W., Wolfer, D. P., Lipp, H. P., Rulicke, T., . . .
Weissmann, C. (1994). Behavioral and anatomical deficits in mice
homozygous for a modified beta-amyloid precursor protein gene. Cell,
79(5), 755-765.
Muller, U. C., & Zheng, H. (2012). Physiological functions of APP family proteins.
Cold Spring Harb Perspect Med, 2(2), a006288. doi:
10.1101/cshperspect.a006288
Muresan, V., & Ladescu Muresan, Z. (2015). Amyloid-beta precursor protein:
Multiple fragments, numerous transport routes and mechanisms. Exp Cell
Res, 334(1), 45-53. doi: 10.1016/j.yexcr.2014.12.014
Murtaugh, L. C., Stanger, B. Z., Kwan, K. M., & Melton, D. A. (2003). Notch
signaling controls multiple steps of pancreatic differentiation. Proc Natl
Acad Sci U S A, 100(25), 14920-14925. doi: 10.1073/pnas.2436557100
Najem, D., Bamji-Mirza, M., Yang, Z., & Zhang, W. (2016). Abeta-Induced Insulin
Resistance and the Effects of Insulin on the Cholesterol Synthesis
Pathway and Abeta Secretion in Neural Cells. Neurosci Bull, 32(3), 227238. doi: 10.1007/s12264-016-0034-9
Nalivaeva, N. N., & Turner, A. J. (2013). The amyloid precursor protein: a
biochemical enigma in brain development, function and disease. FEBS
Lett, 587(13), 2046-2054. doi: 10.1016/j.febslet.2013.05.010

117

Needham, B. E., Wlodek, M. E., Ciccotosto, G. D., Fam, B. C., Masters, C. L.,
Proietto, J., . . . Cappai, R. (2008). Identification of the Alzheimer's disease
amyloid precursor protein (APP) and its homologue APLP2 as essential
modulators of glucose and insulin homeostasis and growth. J Pathol,
215(2), 155-163. doi: 10.1002/path.2343
Obregon, D., Hou, H., Deng, J., Giunta, B., Tian, J., Darlington, D., . . . Tan, J.
(2012). Soluble amyloid precursor protein-alpha modulates beta-secretase
activity and amyloid-beta generation. Nat Commun, 3, 777. doi:
10.1038/ncomms1781
Oh, H., Madison, C., Baker, S., Rabinovici, G., & Jagust, W. (2016). Dynamic
relationships between age, amyloid-beta deposition, and glucose
metabolism link to the regional vulnerability to Alzheimer's disease. Brain,
139(Pt 8), 2275-2289. doi: 10.1093/brain/aww108
Oliveira, L. T., Leon, G. V., Provance, D. W., Jr., de Mello, F. G., Sorenson, M.
M., & Salerno, V. P. (2015). Exogenous beta-amyloid peptide interferes
with GLUT4 localization in neurons. Brain Res, 1615, 42-50. doi:
10.1016/j.brainres.2015.04.026
Oskarsson, M. E., Paulsson, J. F., Schultz, S. W., Ingelsson, M., Westermark, P.,
& Westermark, G. T. (2015). In vivo seeding and cross-seeding of
localized amyloidosis: a molecular link between type 2 diabetes and
Alzheimer disease. Am J Pathol, 185(3), 834-846. doi:
10.1016/j.ajpath.2014.11.016
Pan, J. B., Monteggia, L. M., & Giordano, T. (1993). Altered levels and splicing of
the amyloid precursor protein in the adult rat hippocampus after treatment
with DMSO or retinoic acid. Brain Res Mol Brain Res, 18(3), 259-266.
Parent, M. J., Zimmer, E. R., Shin, M., Kang, M. S., Fonov, V. S., Mathieu, A., . .
. Rosa-Neto, P. (2017). Multimodal Imaging in Rat Model Recapitulates
Alzheimer's Disease Biomarkers Abnormalities. J Neurosci, 37(50),
12263-12271. doi: 10.1523/jneurosci.1346-17.2017
Park, C. R., Seeley, R. J., Craft, S., & Woods, S. C. (2000).
Intracerebroventricular insulin enhances memory in a passive-avoidance
task. Physiol Behav, 68(4), 509-514.
Phinney, A. L., Deller, T., Stalder, M., Calhoun, M. E., Frotscher, M., Sommer, B.,
. . . Jucker, M. (1999). Cerebral amyloid induces aberrant axonal sprouting
and ectopic terminal formation in amyloid precursor protein transgenic
mice. J Neurosci, 19(19), 8552-8559.

118

Plucinska, K., Dekeryte, R., Koss, D., Shearer, K., Mody, N., Whitfield, P. D., . . .
Platt, B. (2016). Neuronal human BACE1 knockin induces systemic
diabetes in mice. Diabetologia, 59(7), 1513-1523. doi: 10.1007/s00125016-3960-1
Porayette, P., Gallego, M. J., Kaltcheva, M. M., Bowen, R. L., Vadakkadath
Meethal, S., & Atwood, C. S. (2009). Differential processing of amyloidbeta precursor protein directs human embryonic stem cell proliferation and
differentiation into neuronal precursor cells. J Biol Chem, 284(35), 2380623817. doi: 10.1074/jbc.M109.026328
Puig, K. L., Brose, S. A., Zhou, X., Sens, M. A., Combs, G. F., Jensen, M. D., . . .
Combs, C. K. (2017). Amyloid precursor protein modulates macrophage
phenotype and diet-dependent weight gain. Sci Rep, 7, 43725. doi:
10.1038/srep43725
Puig, K. L., & Combs, C. K. (2013). Expression and function of APP and its
metabolites outside the central nervous system. Exp Gerontol, 48(7), 608611. doi: 10.1016/j.exger.2012.07.009
Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y., & Combs, C. K. (2012).
Amyloid precursor protein and proinflammatory changes are regulated in
brain and adipose tissue in a murine model of high fat diet-induced
obesity. PLoS One, 7(1), e30378. doi: 10.1371/journal.pone.0030378
Puig, K. L., Kulas, J. A., Franklin, W., Rakoczy, S. G., Taglialatela, G., BrownBorg, H. M., & Combs, C. K. (2016). The Ames dwarf mutation attenuates
Alzheimer's disease phenotype of APP/PS1 mice. Neurobiol Aging, 40,
22-40. doi: 10.1016/j.neurobiolaging.2015.12.021
Puig, K. L., Lutz, B. M., Urquhart, S. A., Rebel, A. A., Zhou, X., Manocha, G. D., .
. . Combs, C. K. (2015). Overexpression of mutant amyloid-beta protein
precursor and presenilin 1 modulates enteric nervous system. J
Alzheimers Dis, 44(4), 1263-1278. doi: 10.3233/jad-142259
Puig, K. L., Manocha, G. D., & Combs, C. K. (2015). Amyloid precursor protein
mediated changes in intestinal epithelial phenotype in vitro. PLoS One,
10(3), e0119534. doi: 10.1371/journal.pone.0119534
Puig, K. L., Swigost, A. J., Zhou, X., Sens, M. A., & Combs, C. K. (2012).
Amyloid precursor protein expression modulates intestine immune
phenotype. J Neuroimmune Pharmacol, 7(1), 215-230. doi:
10.1007/s11481-011-9327-y

119

Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., . . .
Selkoe, D. J. (1998). Insulin-degrading enzyme regulates extracellular
levels of amyloid beta-protein by degradation. J Biol Chem, 273(49),
32730-32738.
Ramaker, J. M., Swanson, T. L., & Copenhaver, P. F. (2016). Manduca Contactin
Regulates Amyloid Precursor Protein-Dependent Neuronal Migration. J
Neurosci, 36(33), 8757-8775. doi: 10.1523/jneurosci.0729-16.2016
Ray, B., Long, J. M., Sokol, D. K., & Lahiri, D. K. (2011). Increased secreted
amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal
of a specific, anabolic pathway and putative biomarker. PLoS One, 6(6),
e20405. doi: 10.1371/journal.pone.0020405
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D.,
Cholerton, B., . . . Craft, S. (2008). Intranasal insulin improves cognition
and modulates beta-amyloid in early AD. Neurology, 70(6), 440-448. doi:
10.1212/01.wnl.0000265401.62434.36
Ribe, E. M., & Lovestone, S. (2016). Insulin signalling in Alzheimer's disease and
diabetes: from epidemiology to molecular links. J Intern Med, 280(5), 430442. doi: 10.1111/joim.12534
Robakis, N. K., Wisniewski, H. M., Jenkins, E. C., Devine-Gage, E. A., Houck, G.
E., Yao, X. L., . . . Brown, W. T. (1987). Chromosome 21q21
sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels
and neuritic (senile) plaques of people with Alzheimer disease and Down
syndrome. Lancet, 1(8529), 384-385.
Rosenbloom, M. H., Barclay, T. R., Pyle, M., Owens, B. L., Cagan, A. B.,
Anderson, C. P., . . . Hanson, L. R. (2014). A single-dose pilot trial of
intranasal rapid-acting insulin in apolipoprotein E4 carriers with mildmoderate Alzheimer's disease. CNS Drugs, 28(12), 1185-1189. doi:
10.1007/s40263-014-0214-y
Sadowski, M., Pankiewicz, J., Scholtzova, H., Ji, Y., Quartermain, D., Jensen, C.
H., . . . Wisniewski, T. (2004). Amyloid-beta deposition is associated with
decreased hippocampal glucose metabolism and spatial memory
impairment in APP/PS1 mice. J Neuropathol Exp Neurol, 63(5), 418-428.
Salameh, T. S., Bullock, K. M., Hujoel, I. A., Niehoff, M. L., Wolden-Hanson, T.,
Kim, J., . . . Banks, W. A. (2015). Central Nervous System Delivery of
Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition. J
Alzheimers Dis, 47(3), 715-728. doi: 10.3233/jad-150307

120

Schilling, S., Mehr, A., Ludewig, S., Stephan, J., Zimmermann, M., August, A., . .
. Eggert, S. (2017). APLP1 Is a Synaptic Cell Adhesion Molecule,
Supporting Maintenance of Dendritic Spines and Basal Synaptic
Transmission. J Neurosci, 37(21), 5345-5365. doi:
10.1523/jneurosci.1875-16.2017
Schirinzi, T., Di Lazzaro, G., Sancesario, G. M., Colona, V. L., Scaricamazza, E.,
Mercuri, N. B., . . . Sancesario, G. (2017). Levels of amyloid-beta-42 and
CSF pressure are directly related in patients with Alzheimer's disease. J
Neural Transm (Vienna), 124(12), 1621-1625. doi: 10.1007/s00702-0171786-8
Schlossmacher, M. G., Ostaszewski, B. L., Hecker, L. I., Celi, A., Haass, C.,
Chin, D., . . . Selkoe, D. J. (1992). Detection of distinct isoform patterns of
the beta-amyloid precursor protein in human platelets and lymphocytes.
Neurobiol Aging, 13(3), 421-434.
Segerstolpe, A., Palasantza, A., Eliasson, P., Andersson, E. M., Andreasson, A.
C., Sun, X., . . . Sandberg, R. (2016). Single-Cell Transcriptome Profiling
of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metab,
24(4), 593-607. doi: 10.1016/j.cmet.2016.08.020
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease
at 25 years. EMBO Mol Med, 8(6), 595-608. doi:
10.15252/emmm.201606210
Selkoe, D. J., Podlisny, M. B., Joachim, C. L., Vickers, E. A., Lee, G., Fritz, L. C.,
& Oltersdorf, T. (1988). Beta-amyloid precursor protein of Alzheimer
disease occurs as 110- to 135-kilodalton membrane-associated proteins in
neural and nonneural tissues. Proc Natl Acad Sci U S A, 85(19), 73417345.
Shen, Y., Joachimiak, A., Rosner, M. R., & Tang, W. J. (2006). Structures of
human insulin-degrading enzyme reveal a new substrate recognition
mechanism. Nature, 443(7113), 870-874. doi: 10.1038/nature05143
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda,
M., . . . St George-Hyslop, P. H. (1995). Cloning of a gene bearing
missense mutations in early-onset familial Alzheimer's disease. Nature,
375(6534), 754-760. doi: 10.1038/375754a0
Shoji, M., Kawarabayashi, T., Sato, M., Sasaki, A., Matsubara, E., Igeta, Y., . . .
Hirai, S. (1998). Accumulation of amyloid beta protein in transgenic mice.
Neurobiol Aging, 19(1 Suppl), S59-63.

121

Shoji, M., Kawarabayashi, T., Sato, M., Sasaki, A., Saido, T. C., Matsubara, E., .
. . Hirai, S. (2000). Age-related amyloid beta protein accumulation induces
cellular death and macrophage activation in transgenic mice. J Pathol,
191(1), 93-101. doi: 10.1002/(sici)1096-9896(200005)191:1<93::aidpath567>3.0.co;2-q
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., . .
. John, V. (1999). Purification and cloning of amyloid precursor protein
beta-secretase from human brain. Nature, 402(6761), 537-540. doi:
10.1038/990114
Sommer, G., Kralisch, S., Lipfert, J., Weise, S., Krause, K., Jessnitzer, B., . . .
Fasshauer, M. (2009). Amyloid precursor protein expression is induced by
tumor necrosis factor alpha in 3T3-L1 adipocytes. J Cell Biochem, 108(6),
1418-1422. doi: 10.1002/jcb.22382
Son, S. M., Song, H., Byun, J., Park, K. S., Jang, H. C., Park, Y. J., & MookJung, I. (2012). Altered APP processing in insulin-resistant conditions is
mediated by autophagosome accumulation via the inhibition of
mammalian target of rapamycin pathway. Diabetes, 61(12), 3126-3138.
doi: 10.2337/db11-1735
Sondag, C. M., & Combs, C. K. (2004). Amyloid precursor protein mediates
proinflammatory activation of monocytic lineage cells. J Biol Chem,
279(14), 14456-14463. doi: 10.1074/jbc.M313747200
Sondag, C. M., & Combs, C. K. (2010). Adhesion of monocytes to type I collagen
stimulates an APP-dependent proinflammatory signaling response and
release of Abeta1-40. J Neuroinflammation, 7, 22. doi: 10.1186/17422094-7-22
Southan, C. (2013). BACE2 as a new diabetes target: a patent review (2010 2012). Expert Opin Ther Pat, 23(5), 649-663. doi:
10.1517/13543776.2013.780032
Stringer, D. M., Zahradka, P., & Taylor, C. G. (2015). Glucose transporters:
cellular links to hyperglycemia in insulin resistance and diabetes. Nutr
Rev, 73(3), 140-154. doi: 10.1093/nutrit/nuu012
Stull, N. D., Breite, A., McCarthy, R., Tersey, S. A., & Mirmira, R. G. (2012).
Mouse islet of Langerhans isolation using a combination of purified
collagenase and neutral protease. J Vis Exp(67). doi: 10.3791/4137

122

Sugimoto, T., Nakamura, A., Kato, T., Iwata, K., Saji, N., Arahata, Y., . . .
Sakurai, T. (2017). Decreased Glucose Metabolism in Medial Prefrontal
Areas is Associated with Nutritional Status in Patients with Prodromal and
Early Alzheimer's Disease. J Alzheimers Dis, 60(1), 225-233. doi:
10.3233/jad-170257
Szot, G. L., Koudria, P., & Bluestone, J. A. (2007). Murine pancreatic islet
isolation. J Vis Exp(7), 255. doi: 10.3791/255
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D.,
. . . Morishita, R. (2010). Diabetes-accelerated memory dysfunction via
cerebrovascular inflammation and Abeta deposition in an Alzheimer
mouse model with diabetes. Proc Natl Acad Sci U S A, 107(15), 70367041. doi: 10.1073/pnas.1000645107
Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., . . .
Arnold, S. E. (2012). Demonstrated brain insulin resistance in Alzheimer's
disease patients is associated with IGF-1 resistance, IRS-1 dysregulation,
and cognitive decline. J Clin Invest, 122(4), 1316-1338. doi:
10.1172/jci59903
Taylor, C. A., Greenlund, S. F., McGuire, L. C., Lu, H., & Croft, J. B. (2017).
Deaths from Alzheimer's Disease - United States, 1999-2014. MMWR
Morb Mortal Wkly Rep, 66(20), 521-526. doi: 10.15585/mmwr.mm6620a1
Teyler, T. J., & Rudy, J. W. (2007). The hippocampal indexing theory and
episodic memory: updating the index. Hippocampus, 17(12), 1158-1169.
doi: 10.1002/hipo.20350
Tharp, W. G., Gupta, D., Smith, J., Jones, K. P., Jones, A. M., & Pratley, R. E.
(2016). Effects of glucose and insulin on secretion of amyloid-beta by
human adipose tissue cells. Obesity (Silver Spring), 24(7), 1471-1479. doi:
10.1002/oby.21494
Tharp, W. G., & Sarkar, I. N. (2013). Origins of amyloid-beta. BMC Genomics,
14, 290. doi: 10.1186/1471-2164-14-290
Tu, Z., Keller, M. P., Zhang, C., Rabaglia, M. E., Greenawalt, D. M., Yang, X., . . .
Zhu, J. (2012). Integrative analysis of a cross-loci regulation network
identifies App as a gene regulating insulin secretion from pancreatic islets.
PLoS Genet, 8(12), e1003107. doi: 10.1371/journal.pgen.1003107
Tups, A., Benzler, J., Sergi, D., Ladyman, S. R., & Williams, L. M. (2017). Central
Regulation of Glucose Homeostasis. Compr Physiol, 7(2), 741-764. doi:
10.1002/cphy.c160015

123

Tyan, S. H., Shih, A. Y., Walsh, J. J., Maruyama, H., Sarsoza, F., Ku, L., . . .
Dickstein, D. L. (2012). Amyloid precursor protein (APP) regulates
synaptic structure and function. Mol Cell Neurosci, 51(1-2), 43-52. doi:
10.1016/j.mcn.2012.07.009
Vagelatos, N. T., & Eslick, G. D. (2013). Type 2 diabetes as a risk factor for
Alzheimer's disease: the confounders, interactions, and neuropathology
associated with this relationship. Epidemiol Rev, 35, 152-160. doi:
10.1093/epirev/mxs012
Vaillant, F., Lauzier, B., Poirier, I., Gelinas, R., Rivard, M. E., Robillard Frayne, I.,
. . . Des Rosiers, C. (2014). Mouse strain differences in metabolic fluxes
and function of ex vivo working hearts. Am J Physiol Heart Circ Physiol,
306(1), H78-87. doi: 10.1152/ajpheart.00465.2013
van der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., & Ramakers, G. M.
(2005). Insulin modulates hippocampal activity-dependent synaptic
plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3kinase-dependent manner. J Neurochem, 94(4), 1158-1166. doi:
10.1111/j.1471-4159.2005.03269.x
Vandal, M., White, P. J., Chevrier, G., Tremblay, C., St-Amour, I., Planel, E., . . .
Calon, F. (2015). Age-dependent impairment of glucose tolerance in the
3xTg-AD mouse model of Alzheimer's disease. FASEB J, 29(10), 42734284. doi: 10.1096/fj.14-268482
Vandal, M., White, P. J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., . . .
Calon, F. (2014). Insulin reverses the high-fat diet-induced increase in
brain Abeta and improves memory in an animal model of Alzheimer
disease. Diabetes, 63(12), 4291-4301. doi: 10.2337/db14-0375
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., . .
. Citron, M. (1999). Beta-secretase cleavage of Alzheimer's amyloid
precursor protein by the transmembrane aspartic protease BACE.
Science, 286(5440), 735-741.
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., . . .
Selkoe, D. J. (2000). Neurons regulate extracellular levels of amyloid betaprotein via proteolysis by insulin-degrading enzyme. J Neurosci, 20(5),
1657-1665.
Walsh, D. M., Minogue, A. M., Sala Frigerio, C., Fadeeva, J. V., Wasco, W., &
Selkoe, D. J. (2007). The APP family of proteins: similarities and
differences. Biochem Soc Trans, 35(Pt 2), 416-420. doi:
10.1042/bst0350416

124

Wang, B., Li, H., Mutlu, S. A., Bowser, D. A., Moore, M. J., Wang, M. C., &
Zheng, H. (2017). The Amyloid Precursor Protein Is a Conserved
Receptor for Slit to Mediate Axon Guidance. eNeuro, 4(3). doi:
10.1523/eneuro.0185-17.2017
Wang, P., Yang, G., Mosier, D. R., Chang, P., Zaidi, T., Gong, Y. D., . . . Zheng,
H. (2005). Defective neuromuscular synapses in mice lacking amyloid
precursor protein (APP) and APP-Like protein 2. J Neurosci, 25(5), 12191225. doi: 10.1523/jneurosci.4660-04.2005
Wang, X., Yu, S., Gao, S. J., Hu, J. P., Wang, Y., & Liu, H. X. (2014). Insulin
inhibits Abeta production through modulation of APP processing in a
cellular model of Alzheimer's disease. Neuro Endocrinol Lett, 35(3), 224229.
Wang, X., Zheng, W., Xie, J. W., Wang, T., Wang, S. L., Teng, W. P., & Wang, Z.
Y. (2010). Insulin deficiency exacerbates cerebral amyloidosis and
behavioral deficits in an Alzheimer transgenic mouse model. Mol
Neurodegener, 5, 46. doi: 10.1186/1750-1326-5-46
Wasco, W., Gurubhagavatula, S., Paradis, M. D., Romano, D. M., Sisodia, S. S.,
Hyman, B. T., . . . Tanzi, R. E. (1993). Isolation and characterization of
APLP2 encoding a homologue of the Alzheimer's associated amyloid beta
protein precursor. Nat Genet, 5(1), 95-100. doi: 10.1038/ng0993-95
Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C.
L., & Beyreuther, K. (1989). Identification, biogenesis, and localization of
precursors of Alzheimer's disease A4 amyloid protein. Cell, 57(1), 115126.
Westermark, P., Wilander, E., Westermark, G. T., & Johnson, K. H. (1987). Islet
amyloid polypeptide-like immunoreactivity in the islet B cells of type 2
(non-insulin-dependent) diabetic and non-diabetic individuals.
Diabetologia, 30(11), 887-892.
Weyer, S. W., Klevanski, M., Delekate, A., Voikar, V., Aydin, D., Hick, M., . . .
Muller, U. C. (2011). APP and APLP2 are essential at PNS and CNS
synapses for transmission, spatial learning and LTP. EMBO J, 30(11),
2266-2280. doi: 10.1038/emboj.2011.119
Wijesekara, N., Goncalves da Silva, R. A., De Felice, F. G., & Fraser, P. E.
(2017). Impaired peripheral glucose homeostasis and Alzheimer's
disease. Neuropharmacology. doi: 10.1016/j.neuropharm.2017.11.027

125

Wirth, M., Bejanin, A., La Joie, R., Arenaza-Urquijo, E. M., Gonneaud, J.,
Landeau, B., . . . Chetelat, G. (2017). Regional patterns of gray matter
volume, hypometabolism, and beta-amyloid in groups at risk of
Alzheimer's disease. Neurobiol Aging. doi:
10.1016/j.neurobiolaging.2017.10.023
Woods, N. K., & Padmanabhan, J. (2013). Inhibition of amyloid precursor protein
processing enhances gemcitabine-mediated cytotoxicity in pancreatic
cancer cells. J Biol Chem, 288(42), 30114-30124. doi:
10.1074/jbc.M113.459255
Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., & Martins,
R. (2002). Alzheimer's beta-amyloid peptides compete for insulin binding
to the insulin receptor. J Neurosci, 22(10), RC221. doi: 20026383
Xu, Y., O'Malley, B. W., & Elmquist, J. K. (2017). Brain nuclear receptors and
body weight regulation. J Clin Invest, 127(4), 1172-1180. doi:
10.1172/jci88891
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., . .
. Gurney, M. E. (1999). Membrane-anchored aspartyl protease with
Alzheimer's disease beta-secretase activity. Nature, 402(6761), 533-537.
doi: 10.1038/990107
Yan, R., Munzner, J. B., Shuck, M. E., & Bienkowski, M. J. (2001). BACE2
functions as an alternative alpha-secretase in cells. J Biol Chem, 276(36),
34019-34027. doi: 10.1074/jbc.M105583200
Yang, Y., Wu, Y., Zhang, S., & Song, W. (2013). High glucose promotes Abeta
production by inhibiting APP degradation. PLoS One, 8(7), e69824. doi:
10.1371/journal.pone.0069824
Young-Pearse, T. L., Bai, J., Chang, R., Zheng, J. B., LoTurco, J. J., & Selkoe,
D. J. (2007). A critical function for beta-amyloid precursor protein in
neuronal migration revealed by in utero RNA interference. J Neurosci,
27(52), 14459-14469. doi: 10.1523/jneurosci.4701-07.2007
Zhang, C. (2017). Developing effective therapeutics for Alzheimer's disease -emerging mechanisms and actions in translational medicine. Discov Med,
23(125), 105-111.
Zhang, Y., Dai, C. L., Chen, Y., Iqbal, K., Liu, F., & Gong, C. X. (2016). Intranasal
Insulin Prevents Anesthesia-Induced Spatial Learning and Memory Deficit
in Mice. Sci Rep, 6, 21186. doi: 10.1038/srep21186

126

Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith,
D. W., . . . Van der Ploeg, L. H. (1995). beta-Amyloid precursor proteindeficient mice show reactive gliosis and decreased locomotor activity.
Cell, 81(4), 525-531.
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H. I., . . .
Rosa-Neto, P. (2017). [(18)F]FDG PET signal is driven by astroglial
glutamate transport. Nat Neurosci, 20(3), 393-395. doi: 10.1038/nn.4492

127

